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Three projects, based on the use of diketopiperazines (DKP) as scaffold for the synthesis of 
small molecules with peptidomimetic character, will be examined in this thesis. 
Our efforts to investigate on the use of these small molecules for the synthesis of 
peptidomimetic ligands for integrins and cadherins to explore modulation of protein-protein 
interactions and functions are described in Part 1.  
In particular, in Part 1 the integrin-targeting properties of c[DKP-RGD] were exploited for 
the synthesis of small molecule drug conjugates. The synthesis of two conjugates bearing 
Daunomycin and Paclitaxel as cytotoxic payloads, was planned and developed in 
collaboration with Professor Neundorf’s group (University of Cologne).  
Furthermore, synthesis of linear and cyclic DKP-based inhibitors for cadherin-mediated 
homophilic interactions has been described in this part of the thesis.  
Finally, the drug delivery properties of the cell penetrating peptide sC18* were employed in 
the synthesis of drug delivery systems and are reported in Part 2. Two cyclic cell penetrating 
peptides, bearing DKP scaffolds with different stereochemistry, were synthesized in 
collaboration with Professor Neundorf’s group. 
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PART I 
 
I.1 General aspects of PPIs modulation 
 
Proteins involved in biological functions did not act alone and their functions tend to be regulated 
mostly through the formation of protein-protein complexes. Factors that influence the formation of 
different protein-protein complexes were studied since 1996.1 Several complexes were compared 
and the diversity reflected their role in different biological functions. Up to date, several 
experimental methods, together with bioinformatic tools, were used to determine protein-protein 
interactions (PPIs).1–4 
PPIs refers to physical contact, not accidental, established between protein interfaces as a result of 
non-generic biochemical events.2 In this way cells can control numerous cellular processes such as 
chemotaxis, proliferation, differentiation, endocytosis and apoptosis; they are also involved in 
oncogenic signalling network leading to tumor progression as their misregulation can result in 
numerous tumor diseses.5 
The design of structural mimetics of the active portions in the PPIs has proven an effective mean to 
modulate protein functions.5,6 To date, PPI inhibition with small molecules (such as 
peptidomimetic ligands) is a novel and effective strategy towards drug development.7,8 As a matter 
of fact, the number of pubblications on this field is growing and growing in the last few decades. 
The mimetic approach involves the synthesis of molecules, with defined dimensions, to target 
protein surface, which includes specific amino acid residues. The space in which the targeting 
happens is also known as “hot spot”. For example, α-helices are important recognition sites on 
protein surfaces for different interactions (protein-DNA, protein-protein…) which were found to be 
characterized by conserved structural features within the α-helical domain.6 
More recently, structural conservation of the “hot-spots” was established.9 In fact, hot spots are 
different from other regions of the protein surface due to their incurve topology and a mosaic-like 
pattern of hydrophobic and polar functionality. This combination of properties confers on the hot 
spots a tendency to bind organic compounds with different structures.9 
Many recent success studies showed that small molecules, with drug-like potencies, bind to “hot 
spots” on the surfaces involved in protein–protein interactions.10,11 
Structure-based design is therefore essential for developing PPI inhibitors, especially when peptide 
binding epitopes are the starting point in the design process.12 Different strategies were used for the 
structure-based design of PPI inhibitors, which include mimicking or simply stabilizing β-sheets, 
helices and turns. For example, macrocyclization and β-hairpin inducers are useful to mimick or 
stabilize β-sheets,13 while thiol-based and lactam cross-linkers can be used to stabilize α-helices.12 
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Figure 1. Families of Cell Adhesion Molecules. 
Cell adhesion molecules (CAMs) 
 
Cell adhesion underlies tissue formation as it is one of the key processes in different cell activity as 
morphogenesis, cell division, apoptosis. Since cell adhesion molecules (CAMs) are essential in 
intercellular protein-protein interactions, they 
also play a key role in cell life and survival;14 
for example chemical synapses, through which 
neurons transfer electrical and chemical 
signals to other cells, are based on interactions 
of CAMs.15 Cell adhesion molecules are 
mostly transmembrane proteins, including four 
protein classes: integrins, cadherins, 
immunoglobulins and selectins (Figure 1). 
Integrins are transmembrane heterodimeric 
glycoproteins which mediate events like cell 
proliferation and migration; cadherins are 
calcium-dependent adhesive transmembrane 
proteins, which promote cell-cell adhesion by forming homophilic interactions between the N-
terminal domains of two proteins on adjacent cells. Immunoglobulins are produced by plasma cells 
and lymphocites and are essential for body’s immune system. Selectins recognize and bind sugar 
moieties and act in leukocyte trafficking.  
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1 Integrin ligand-based conjugates for targeted cancer therapy 
 
1.1 Integrin receptors and ligands 
 
Integrins are transmembrane receptors comprising non-covalent heterodimers, which mediate cell 
adhesion to extracellular matrix (ECM) proteins and other cells. They are involved in physiological 
and pathological situations such as angiogenesis, tumor growth, transmembrane connection to the 
cytoskeleton, activation of many intracellular signalling pathways, embryological development, 
hemostasis, thrombosis, wound healing, immune and nonimmune defence mechanisms, etc. They 
are also receptors for many viruses and bacteria. Since their identification as a receptor family,16 
they have become the best-understood cell adhesion receptors. Recently it was demonstrated that 
malignant cells’ proliferation, migration, survival and aggressiveness, are triggered essentially by 
the ECM and so also by integrins. The importance of these integrins as potential therapeutic targets 
as well as in the regulation of breast cancer cells differentiation has been established.17 
Integrins are bi-directional allosteric signalling molecules in the sense that they transfer 
information from the extracellular environment (“outside-in” causing adhesion, spreading, 
migration, growth and survival signalling, invasion) and from the cytoplasm (“inside-out”) to 
modulate cell activity through long-range allosteric conformational changes.18,19 
Integrins consist of α- and β-subunits; each subunit crosses the membrane once, with a large 
polypeptide in the extracellular space and a short cytoplasmic tail. Figure 2 shows the subunits and 
their associations; 8 β-subunits pair together with 18 α-subunits in a non-covalent manner to form 
24 distinct integrins. The α-subunit seems to be important in defining the ligand binding properties 
of integrins.18,20 
 
Figure 2. The integrin families and their ligands.18 
Integrins exist in different conformational states in equilibrium between each other; in particular, 
the equilibrium between its inactive and active forms are showed in Figure 3. Conformational 
changes expose the external ligand-binding site (between the α- and β-subunit) to which ligands 
bind, allowing the transmission of signals from the outside to the inside. In particular, in the inside-
out direction, activating signals induce conformational changes of the integrin extracellular domain 
and force integrin to pass from a resting to an active state.21,22 In the outside-in direction, ligand 
binding to the extracellular domain of active integrin also induces long-range conformational 
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changes, which lead to association and activation of kinases and the transmission of signals in the 
cytosol.22,23  
 
 
Figure 3. Representation of integrin states.24 
Integrin binding with endogenous ligand is essential for their role; the great variety of integrin 
ligands includes ECM proteins (fibronectins, laminins, collagens, RGD receptors, etc), ICAMs and 
VICAMs receptors but also microorganisms (adenoviruses, echoviruses) can enter cells via 
integrins.25 Actually, the classification of integrins showed in Figure 2 is done considering that 
each integrin recognizes a specific type of endogenous ligand. 
Integrins αvβ3, α5β1 and αvβ6 are usually expressed at low levels in healthy tissues and in the 
same time they were found to be abundant on membrane of cancer cells.26  
Among the great variety of integrins, αVβ3 has been extensively studied and it has been found that it 
is mostly expressed in angiogenic vasculature. During angiogenesis, regulation of the matrix-
metalloproteinase-2 (MMP-2) on the surface of angiogenic blood vessels is mediated by integrin 
αVβ3 resulting in collagen degradation and ECM reorganization to form new vessel for the cancer 
cells.27 As a consequence, the integrin αVβ3 antagonism with either functional blocking antibodies 
or ligand-mimetic peptides have shown promising antiangiogenic and antitumor effects.28 
Different approaches were studied to inhibit integrin function: impeding ligand binding, blocking 
downstream integrin signalling, but also modulating integrin expression. The most applied 
approach is to block the binding site with peptidomimetic ligands. 
 
1.1.1 RGD-integrin ligands 
 
Endogenous ligands bearing the tripeptide sequence RGD (Figure 4) have become very important 
in the therapeutic field, with implications in fibrosis, thrombosis, cancer, and other diseases.20 The 
RGD sequence interacts with different integrin receptors related to tumor angiogenesis and cancer 
development such as αVβ3, αVβ5 and α5β1.29 
The importance of the RGD sequence was established in 1984 
when Pierschbacher and Ruoslahti found that the ability of 
fibronectin to recognize its target receptors on cell membrane was 
accounted by this particular recognition motif (Figure 4).29 Since 
then, different peptide and peptidomimetic libraries have been 
Figure 4 RGD recognition motif. 
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developed. The presentation of the RGD sequence in the binding site is important and it is a 
common feature for all the RGD proteins. Higher rigidity of the backbone and low flexibility of 
flanking residues, needed to properly fold the RGD sequence, were obtained in different ways; 
blocking the RGD sequence in a cyclic structure was the most used. Among the great variety of 
RGD peptidomimetic ligands found in literature, Cilengitide (Figure 5) is the most famous. It was 
developed by the research group of Professor Kessler as a potent integrin ligand in 199130 with 
high binding affinity for ανβ3 (IC50 ανβ3 = 0.61 ± 0.06 nM) and ανβ5 (IC50 ανβ5 = 8.4 ± 2.1 nM) and 
sub-nanomolar antagonistic activity for the ανβ3 receptor.31,32 
Cilengitide has been the first integrin ligand to be tested for antagonistic behaviour in clinical trials; 
it failed phase III clinical trial for treatment of patients with glioblastoma,33 but it is currently 
undergoing phase II studies for the treatment of other 
tumors.34–36 The interaction mechanism by which RGD 
ligands bind the integrin receptor was studied by Xiong 
et al through X-ray analysis.37 The crystal structure of the 
isolated ανβ3 co-crystalized with Cilengitide was obtained 
and some key interactions were established. A distance 
of about 9 Å between the Cβ atoms of the arginine and 
the aspartic acid was necessary in order to allow the 
following interactions shown in Figure 6: the guanidine 
group of arginine interacts with two aspartic acid residues (Asp 218 and Asp 150 of the α-subunit), 
whereas the aspartic acid binds to Mn2+ in the MIDAS (metal-ion dependent adhesion site) region 
of the β-subunit. These interactions, which were then addressed as “electrostatic clamp”, proved to 
be essential to obtain ligand-protein interaction. 
 
 
 
In principle all the RGD ligands, presenting the RGD motif in the proper conformation, can interact 
with the integrin binding site. On these basis, a great variety of RGD ligands were designed in 
order to develop anti-angiogenic agents; some examples are reported in Figure 7, which is not an 
exhaustive list of these integrin ligands. 
Figure 5 Cilengitide. 
Figure 6 Crystal structure of the ανβ3 receptor complexed with
Cilengitide (in yellow). Adapted from ref 37 
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Figure 7 Few examples of integrin ligands (238, 339, 440, 541, 642) and their relative integrin affinity (IC50 values). 
 
Although the great activity of these and others integrin ligands versus angiogenesis, inconsistent 
observations were found regarding the enhanced tumor growth observed on integrin β3-deficient 
mice.43 Furthermore, low concentrations of RGD-mimetic integrin αvβ3 inhibitors stimulate tumor 
growth and angiogenesis in mice.28,44 Cilengitide’s question itself has turned to be controversial 
despite cilengitide is well tolerated and non toxic; it showed to act as agonist of angiogenesis in 
low concentrations, compromising its antiangiogenic effects.45 
Anyway, a different way of use of these small molecules, exploiting the αvβ3 over expression on the 
membrane of tumor cells, has become attractive. As a matter of the fact, they can be seen as vectors 
to selectively deliver imaging agents46,47 and also chemotherapeutics48,49. 
Starting from 2009, our research group together with the research group of Professor Gennari from 
University of Milan developed low nanomolar peptidomimetics RGD integrin ligands. 
2,5-diketopiperazine (DKP) bifunctional scaffolds were used to display the RGD sequence in the 
proper conformation for targeting integrins. Among the great variety of conformationally 
constrained scaffolds which have been used to develop ligands for integrins, or in general for PPI’s 
modulation, DKP have shown very promising properties. In fact, the structural similarity of DKP to 
peptides opens a new way for medicinal chemistry in designing molecules with similar 
characteristics. Reducing the susceptibility to metabolic amide bond cleavage and inducing 
conformational rigidity are the results of constraining the nitrogen atom of an α-amino amide into a 
DKP ring. Functional diversity and stereochemistry can be introduced at different positions. A 
DKP library was developed in our research group (Figure 8).50,51 These DKPs differ for the 
stereochemistry at C3 and C6 and for the substitution on the endocyclic nitrogens. 
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Figure 8 DKP1-DKP8 scaffold library50,51 
 
Based on these DKP scaffolds, a small library of cyclic(DKP-RGD) integrin ligands were 
synthesized by our group exploiting the two carboxylic and amino functions (Figure 9).52,53  
 
Figure 9 c[DKP-RGD] peptidomimetics (7-14). 
All the ligands were tested in vitro for their ability to inhibit biotinylated vitronectin binding on the 
isolated αvβ3 and αvβ5 integrin receptors (see Table 1). Vitronectin is an endogenous integrin 
ligand. In particular, compounds 8-14, bearing the trans-DKP scaffolds (DKP2-DKP7), were 
qualified as low nanomolar ligands for αvβ3. They also showed a higher αvβ3/αvβ5 selectivity with 
respect to the Cilengitide (1, Figure 5) taken as reference ligand.  
The differences in the binding ability among the different compounds 8-14 were elucidated by 
NMR spectroscopy experiments and MC/SD (Monte Carlo/Stochastic Dynamics) simulations. The 
binding ability is essentially due to the intramolecular H-bonds formed and to the extended 
conformation of the RGD motif, as for Cilengitide. The ligands with the best pose of the RGD 
motif (particularly a distance of 9 Å between Cβ(Arg) and Cβ(Asp) was found) are the ones with the 
highest affinity values.  
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Compound Structure ανβ3 IC50 [nM] 
ανβ5 IC50 
[nM] 
7 c[DKP1-RGD] 3898 ± 418 >104 
8 c[DKP2-RGD] 3.2 ± 2.7 114 ± 99 
9 c[DKP3-RGD] 4.5 ± 1.1 149 ± 25 
10 c[DKP4-RGD] 7.6 ± 4.3 216 ± 5 
11 c[DKP5-RGD] 12.2 ± 5.0 131 ± 29 
12 c[DKP6-RGD] 2.1 ± 0.6 79 ± 3 
13 c[DKP7-RGD] 0.2 ± 0.09 109 ± 15 
14 c[DKP8-RGD] 7.5 ± 0.0 >103 
Cilengitide c(RGDfV) 3.2 ± 1.3 7.5 ± 4.8 
 
Table 1 Binding affinity of compounds 7-14 on isolated receptor. 
 
C[DKP3-RGD] 9 was further analyzed in vitro on HUVEC (Human umbilical vein endothelial 
cells) and it was found to efficiently inhibit angiogenesis also in the presence of pro-angiogenic 
growth factors without affecting other cellular aspects such as proliferation and cell viability.54  
It was also found that compound 9 significantly inhibit the phosphorylation of Akt (protein kinase 
important in the regulation of vascular angiogenesis),54 FAK/Akt integrin-activated transduction 
signalling pathway and integrin-mediated cell infiltration process in U373 (human glioblastoma) 
cell line.55 This results increased the interest toward c[DKP3-RGD] 9 as true integrin αvβ3 
antagonist. With the aim to use 9 as potential vehicle for delivery cytotoxic agents, the DKP3 
scaffold was modified on the benzyl moiety, obtaining the c[DKP3-RGD]-CH2-NH2 functionalized 
ligand 15 named c[DKPf3-RGD] (Figure 10).56 
 
 
Figure 10 c[DKPf3-RGD] integrin ligand (15). 
 
The amino group on the benzylic moiety has been used as linkage point for further 
functionalizations and in particular for developing SMDCs (small molecule drug conjugates) 
targeting the αvβ3 receptor.48,57,58 
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1.1.2 RGD-based integrin ligands as SMDCs 
 
Small molecule drug conjugates are small vehicles for targeted drug delivery and they are 
composed by low-molecular weight targeting ligands covalently conjugated to a cytotoxic agent 
through a suitable linker (Figure 11a).59 
 
 
 
 
 
 
 
 
Figure 11 General structure of SMDCs (a). Adapted from ref 59. General mode of action for the SMDCs internalization 
(b). Adapted from ref 60. 
In some cases, additional linker spacers can be added when there is the necessity to enhance 
solubility in aqueous media or to improve the drug release. The internalization mechanism has been 
described in 2013 (Figure 11b).60 Generally, the ligand binds to the target on the cell membrane to 
form a complex which is then internalized in a vesicle. Its fusion with the early endosome may 
release the drug (if pH-dependent linker system is present), or it may proceed to the lysosome in 
which proteases hydrolize amide and ester specific bonds releasing the drug. The drug needs to be 
expelled outside the endosome or lysosome (normally by passive diffusion) in order to act on the 
target.60 
The linker strategy as well as the choice of the drug and the targeting ligand are key factors for 
developing an effective drug delivery system. Different types of linkers can be used: acid sensitive 
(e.g. esters or hydrazones), enzimatically-cleavable linkers (e.g. Val-Ala, Val-Cit, GFLG), disulfide 
linkers (reduced by Glutathione), etc. 
Many examples of RGD-drug conjugates can be cited,61–66 including the work developed by our 
research group in the field.52,56–58,67,68 Some of them are described in the following section. 
 
- RGD-Paclitaxel (PTX) conjugates 
Paclitaxel (PTX, Figure 12) is one of the most effective antineoplastic agents for treatment of 
many cancers. It is effective on both solid and disseminated 
tumors thanks to the particular mechanism of action. Its 
antitumor efficacy is due to the combination of 
antiproliferative and cytotoxic properties. In fact, it hampers 
tumor angiogenesis and also it binds selectively the tubulin 
proteins promoting their stabilization; the latter leads to 
disruption of microtubules, thus inducing mitotic arrest which 
Figura 12 Structure of PTX. 
17 
 
 
eventually leads to cell death. The OH group in position 2’ is essential for the biological activity 
and represents an ideal position for the insertion of functional groups to create prodrugs or 
conjugates.69 Having synthesized peptidomimetic ligands targeting αvβ3 receptor with high affinity 
(15, Figure 10) Gennari and Piarulli’s research group developed the c[DKPf3-RGD]-PTX 
conjugate (Figure 13a). Paclitaxel was linked to the DKPf3-RGD targeting moiety by an acid-
labile ester bond through a succinate fragment. The conjugate retained a low nanomolar affinity 
and a high selectivity for αvβ3 receptor (IC50 αvβ3: 5.2 nM; IC50 αvβ5: 219 nM). Moreover, in vivo 
test on compound a in nude mice xenografted with IGROV-1/Pt1 cancer cells (αvβ3 over-
expressing cells) showed that conjugate a (Figure 13) was more effective than free PTX.56 
 
 
Figure 13. c[DKPf3-RGD]-PTX conjugates (a-d) developed in Gennari and Piarulli’s research group. 
 
PTX was also linked to c[DKPf3-RGD] through lysosomally cleavable linkers: Val-Ala and Phe-
Lys (Figure 13b-c). The conjugates were stable at different pH conditions and showed an efficient 
linker cleavage and release of the drug after treatment with lysosomal extract. The integrin 
targeting affinity of the conjugates was suggested as their antiproliferative activity was similar to 
free PTX with an increased potency in CCRF-CEM (αvβ3+) compared to the negative cell line. The 
conjugate d in Figure 13 contains an ‘uncleavable’ nonpeptide linker. It was synthetized as a 
negative control of the linker efficacy and showed no cytotoxicity. In the competitive binding 
assay, the three conjugates displayed slightly lower binding affinity than the unconjugated ligand 
15, remaining in the low nanomolar range and conserving the selectivity towards αvβ3 compared to 
αvβ5.48  
To note the presence of a self-immolative linker between the PTX moiety and the peptide linker. It 
offers an elegant mechanism of releasing the free PTX inside the cells; once the conjugate reaches 
lysosomes, cathepsin B proteases hydrolize the C-terminus of the dipeptide linker (Figure 14). A 
fast electron cascade takes place in the aniline ring, releasing CO2 and forming a stable free amine. 
Finally, a slow cyclization step liberates the free paclitaxel in the tumor cell. 
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Figure 14. Enzymatic cleavage and drug release of PTX prodrug containing the peptide linker Phe–Lys. 
 
- RGD-Doxorubicin (DOX) conjugates 
In 2008, Ryppa and co-workers70 reported the synthesis of two DOX-E[c(RGDfK)]2 conjugates. 
DOX was attached to the ligand through an amide bond (Figure 15a) or a MMP2/MMP9 cleavable 
octapeptide linker was used (Figure 15b). The conjugate bearing the protease cleavable linker 
demonstrated to be more efficient in the HUVEC antiproliferative, but in vivo it displayed only a 
moderate antitumor activity compared to free DOX.  
 
Figure 15. RGD-DOX conjugates (a, b) developed by Ryppa and co-workers. 
 
a 
b 
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- RGD-Camptothecin (CPT) conjugates 
In 2017, the synthesis of the new c[DKP-RGD]-Naph-S-S-CPT conjugate57 (Figure 16b) and its 
biological evaluation compared to the previously reported conjugate c[RGDyK]-Naph-S-S-CPT 
(Figure16a)71 was reported by Gennari’s research group. The two conjugates were able to bind the 
purified integrin αvβ3 at nanomolar concentrations. The internalization process was also 
investigated thanks to the fluorescent moiety present in the conjugates; U87 (human glioblastoma, 
αvβ3 +) cells and U87 clone non expressing αvβ3 were chosen. Internalization was found to be not 
dependent on the αvβ3 expression as it was detected for both cell lines. Moreover, due to the 
premature cleavage of the disulfide linker and the release of the free CPT, conjugates a and b were 
not stable in the cell media.57 
 
 
Figure 16. RGD-CPT conjugates (a, b). 
 
Many other RGD-drug conjugates were developed bearing the previously reported drugs and new 
other drugs such as mono Monomethyl auristatin E and F.49,72 
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1.2 Aim of the project 
Considering the great potential of c[DKPf3-RGD] 15 (Figure 10) as targeting integrin ligand, we 
decided to use it and develop novel drug-conjugates exploring different linker strategies and two 
different cytotoxic payloads, Daunomycin and Paclitaxel. 
 
Daunomycin (or Daunorubicin, Dau, Figure 17) is an anthracycline anticancer drug which 
intercalates between the base pair of the DNA interfering with its functions and replication.73 
Despite its high efficiency, daunomycin has numerous side effects, in particular cardiotoxic 
effects.74 Anyway, daunomycin’s cardiotoxicity is lower than the one of doxorubicin.75 It was 
demonstrated that coupling the drug to peptide carrier could 
improve solubility, decreases side effects and offers the 
possibility to enhance selectivity by targeting tumor cells.76,77 
Following this approach, we planned to link Dau to our 
c[DKPf3-RGD] (15) previously reported by our group. 
Considering that modification of the amino group on the 
sugar moiety of the Dau might lead to loss of bioavailability 
of the compound78, the oxo group at the C-13 position was 
used as conjugation site. Two conjugates (16 and 17, Figure 
18) were synthesized and in both cases Dau was linked to the targeting moiety via oxyme linkage 
through two aminooxyacetylated peptides. In the case of the conjugate 16, the targeting moiety is 
directly linked to Dau, without any cleavable linker through the dipeptide PropargylGly-Aoa which 
corresponds to the minimum peptide sequence necessary to link Dau and the targeting moiety. On 
the other hand, compound 17 displays the c[DKPf3-RGD] linked to Dau through the Aoa-GFLG 
cleavable linker, with the aim to investigate whether the presence of a cleavable linker is required 
for the antitumor activity of the conjugates. The GFLG linker is degraded by lysosomal enzymes 
ensuring the release of the Dau=Aoa-Gly-OH as the smallest bioactive metabolite in lysosomes.79 
In fact, previous studies demonstrated that not only the free Dau but also Dau containing 
metabolites, such as Dau=Aoa-Gly-OH, bind to DNA efficiently, thus presenting antitumor 
activity.79,80 
 
 
Figure 17. Daunomycin structure 
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Figure 18 Conjugates c[DKPf3-RGD]-PEG-4-PropargylGly-Aoa-DAU 16 and c[DKPf3-RGD]-PEG-4-GLFG-Aoa-
DAU 17; in blue the targeting moiety, in green the Dau. 
 
For what concern the Paclitaxel conjugate, different strategies were previously adopted in Gennari 
and Piarulli’s group in order to improve the cytotoxicity of c[DKPf3-RGD]-Paclitaxel conjugates; 
an acid-labile ester bond through a succinate fragment was initially used to link PTX to the 
targeting moiety56, as previously described in Paragraph 1.1. Because of the poor stability of this 
ester in circulation, the insertion of lysosomally cleavable linkers (Val-Ala or Phe-Lys), was 
employed as they show high plasma stability and they are rapidly cleaved upon endocytosis by 
tumor-associated extracellular or lysosomal cysteine proteases.48 As a further step, multivalency 
was considered to improve binding affinity of RGD ligand to integrin αvβ3.68 In fact, through 
linking PTX to two to four c[DKPf3-RGD] ligands was demonstrated to be an effective strategy to 
enhance targeting and thus cytotoxicity.  
Among these strategies, we decided to use the well known cell penetrating properties of the peptide 
sC18 to develop a c[DKPf3-RGD]-PTX conjugate with the aim to improve the CPP-mediate 
internalization and in consequence cytotoxicity. Conjugate 18 is represented in Figure 19; it was 
designed to release PTX intra-cellularly by means of a self-immolative spacer (PABC-N,N’-di-
methylethylene diamine) and a lysosomally cleavable dipeptide linker (Val-Ala), which connects 
PTX to an heterobifunctional cross linker, N-(-2-aminoethyl) maleimide. As sC18 was equipped 
with a β-alanine-cysteine dipeptide on Lys13, the maleimide group can react with the thiol group of 
the cysteine, thus connecting the c[DKPf3-RGD]
 
15 which is, in turn, linked to the sC18 through a 
PEG-4 N3 spacer.  
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Figure 19 conjugate c[DKPf3-RGD]-Ptx (18) bearing sC18 and a self immolative linker. 
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1.2.1 Synthesis of the functionalized c[DKP-RGD] integrin ligand 15 
 
- Synthesis of DKPf3 scaffold (28) 
Synthesis of the DKP-f3 scaffold is presented in Scheme 1, starting from commercially available 
D-aspartic acid 19 and L-serine methyl ester 21.56 Side chain of the aspartic acid was protected 
with the allyl group before N-Boc protection, giving compound 20. Aldehyde 22 underwent a 
reductive amination with L-serine methyl ester using sodium triacetoxyborohydride to obtain the 
functionalized serine 23. Intermediates 20 and 23 reacted under direct coupling conditions (HATU, 
HOAt, DIPEA) to afford the isopeptide 24 in high yield (80%). The selective acylation of the 
unprotected β-hydroxy group of the functionalized serine occurs instead of the expected peptide 
bond formation, as reported also in the synthesis of DKP1-3.52,81 Once Boc protecting group of 24 
was cleaved, O,N-acyl migration and subsequent ring closure were prompted by treatment with 
DIPEA in a protic solvent (isopropyl alcohol)81, giving the DKP-f3-OH 25 (84% over two steps). 
The hydroxyl group of 25 was substituted by an azide group via a Mitsunobu reaction using HN3 as 
nucleophile, affording compound 26 in satisfactory yield (60%). The reaction was carried out at 
low temperature (-20°C) to avoid the formation of the elimination by-product. An one-pot 
Staudinger reduction-Boc protection allowed to reduce the azide under mild conditions and directly 
attack the 2-(t-butoxy-carbonyl-oxyimino)-2-phenylacetonitrile (Boc-ON) present in the medium, 
affording the DKP-f3-NHBoc 27 in good yield (88%). Finally, allyl deprotection yielded the trans 
DKPf3 scaffold 28 in 85% yield. 
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Scheme 1. Synthesis of DKPf3 scaffold (28): a) Allyl alcohol, acetyl chloride; b) Boc2O, TEA, dioxane, water, 95% over 
two steps; c) aldehyde 22, NaBH(OAc)3, THF, 3 h, r.t., quant.; d) HATU, HOAT, DIPEA, DMF, 3 h, 0 °C to r.t. 80%; e) 
TFA/DCM 1:2, 3 h, 0 °C to r.t.; f) DIPEA, iPrOH, overnight, r.t., 84% over two steps; g) HN3· in Tol, DIAD, Ph3P, 
DCM/Toluene 1:2, 4 h, -20 °C, 60%; h) Me3P, BOC-ON, THF, 3 h, -20 °C to r.t., 88%; i) pyrrolidine, PPh3, [Pd(PPh3)4], 
DCM, 4h, 0 °C to r.t., 85%. 
 
- Synthesis of c[DKPf3-RGD] (15) 
Diketopiperazine DKPf3 was used as scaffold for the synthesis of functionalized c[DKPf3-RGD] 
integrin ligand 15 (Figure 10), following a solution phase strategy (Scheme 2). Dipeptide Boc-
Arg(Mtr)-Gly-OBn, prepared following a reported procedure52, was Boc-deprotected and coupled 
to 28 to give compound 29 in good yield (85%). The Boc protecting group of compound 29 was 
then removed and the resulting free amine was coupled to Cbz-Asp(OtBu)-OH to obtain the linear 
peptidomimetic ligand 30 in high yields (89%). After carboxybenzyl and benzyl groups 
simultaneous deprotection by catalytic hydrogenolysis to give compound 31 quantitatively, the 17-
membered macrolactamization in highly diluted DMF solution (1.4 mM) using HATU, HOAt and 
DIPEA (4:4:6) yielded the protected cyclo 32 in good yield (68%). The final step was the removal 
of the side chain protecting groups using TFA/TMSBr/thioanisol/EDT/phenol 70:14:10:5:1, 
obtaining 15 in satisfactory yield (70%).  
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Scheme 2. Synthesis of c[DKPf3-RGD] (15): a) Boc-Arg(Mtr)-Gly-OBn, HATU, HOAT, DIPEA, DMF, o.n., r.t., 85%; 
b) Cbz-Asp(OtBu)-OH, HATU, HOAT, DIPEA, DMF, o.n., r.t., 89%; c) H2, 10% Pd/C, THF/water 1:1, o.n., r.t., quant.; 
d) HATU, HOAT, DIPEA, 1.4 mM in DMF, o.n., r.t., 68%; e) TFA/TMSBr/thioanisol/EDT/phenol 70:14:10:5:1, 2h, r.t., 
70%. 
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1.3 Daunomycin conjugates  
1.3.1 Synthesis 
 
C[DKPf3-RGD]-PEG-4-N3 (34, Scheme 3) was prepared by pH-controlled coupling between the 
RGD ligand 15 and COOH-PEG-4-azide pre-activated as NHS ester (33, using EDC HCl and 
NHS). The pH was maintained around 7.3-7.6, with the addition of small amounts of NaOH 0.2 M, 
in order to prevent the hydrolysis of the NHS ester which can compete with the formation of the 
amide bond at pH > 7.6. Furthermore, in these conditions the guanidinium group of the arginine 
residue is protonated so that it does not compete with the primary benzylic amine of compound 15. 
 
 
 
Scheme 3 Synthesis of intermediate c[DKPf3-RGD]-PEG-4-N3 (34). a) PBS (pH 7.5), o.n., r.t., 40%.  
 
Compound 16 was then synthesized as reported in Scheme 4. Rink amide resin (100-200 mesh, 
loading: 0.48 mmol/g, 144 µmol scale) was manually loaded with the Fmoc-propargylGly-OH. 
After a capping procedure to block the unreacted groups on the resin (acetic anhydride and DIPEA 
in DMF), Fmoc deprotection of the amino acid with 30% solution of piperidine in DMF (35, 
Scheme 4) was done. BisBoc-Aminooxyacetic acid was then manually coupled twice (Oxyma, 
DIC in DMF for 2 h) (36). Full cleavage of the peptide from the resin was done using 
TFA:TIS:water 90:2.5:2.5 (v/v/v) in the presence of 5 eq Boc-Aoa-OH. Dau was coupled to the 
aminooxyacetilated peptide 37, dissolving the peptide in 0.2M NH4OAc (10 mg/mL, pH 5), 
yielding intermediate 38. After HPLC purification, 38 was linked to c[DKPf3-RGD]-PEG-4-N3 34 
through CuAAC reaction, yielding final conjugate 16 in 56% yield. 
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Scheme 4. Synthesis of conjugate c[DKPf3-RGD]-PEG-4-PropargylGly-Aoa-DAU (16). a) bisBoc-Aoa-OH 3 eq, oxyma 
3 eq, DIC 3 eq, in DMF, 2h, r.t.; b) TFA:TIS:water 90:2.5:2.5 (v/v/v), 5eq Boc-Aoa-OH, 30%; c) 0.2M NH4OAc (pH 5) 
at a peptide concentration of 10 mg/mL, Dau 30% excess, 64%; d) peptide 38 (1.3 eq), c[DKPf3-RGD]-PEG-4-N3 (1 eq), 
sodium ascorbate, CuSO4 5H2O, tert-buthanol/H2O 1:1, o.n., 56%. 
 
Synthesis of compound 17 is reported in Scheme 5. The GFLG tetrapeptide was synthesized as C-
terminal acid on a 2-chlorotrytil chloride resin (H-Gly-2CT Resin, 100-200 mesh, 0.87mmol/g, 
0.015 mmol scale) by automated multiple solid-phase peptide synthesis (Fmoc strategy). BisBoc-
Aminooxyacetic acid was coupled manually to the peptide using 3 eq. of the reagent, 3 eq. Oxyma 
and 3 eq. DIC for 2 h and the procedure was repeated twice (40, Scheme 5). Full cleavage of the 
peptide from the resin was done using TFA:TIS:water 90:2.5:2.5 in the presence of 5 eq Boc-Aoa-
OH in order to avoid the formation of the acetone adduct with m/z = +40.82 The peptide 41 was 
lyophilized from water:tert-butyl alcohol (1:3 v/v) and purified by preparative RP-HPLC (50-90 
ACN in 45 min). The peptide was let to react with acetone in order to protect the Aoa moiety as 
isopropyliden group (42). C[DKPf3-RGD] 15 was then coupled to the C-terminus of the peptide 
using BOP and DIPEA in DMF, obtaining compound 43. The isopropyliden group was then 
cleaved from the Aoa dissolving the peptide in 1M CH3ONH2 HCl containing NH4OAc-buffer (0.2 
M, pH 5) (20 eq at least). The reaction mixture was then directly purified by semi-preparative 
HPLC. Finally, Dau (30% excess) was coupled to the deprotected aminooxyacetylated peptide, 
dissolving the peptide in 0.2M NH4OAc (10 mg/mL, pH 5), yielding conjugate 17 in 50% yield 
after HPLC purification. 
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Scheme 5. Synthesis of conjugate c[DKPf3-RGD]-GLFG-Aoa-DAU 17. a) bisBoc-Aoa-OH 3 eq, oxyma 3 eq, DIC 3 eq, 
in DMF, 2h, r.t.; b) TFA:TIS:water 90:2.5:2.5 (v/v/v), 5 eq Boc-Aoa-OH, 80%.; c) aceton, 2h, 92%; d) peptide 2 eq, 
cyclo[DKPf3-RGD]-CH2NH2 1 eq, BOP 1.8 eq, DIPEA 5 eq in DMF, 28%; e) 1M CH3ONH2 HCl in NH4OAc-buffer 
(0.2 M, pH 5),88%; f) 0.2M NH4OAc (pH 5) at a peptide concentration of 10 mg/mL, Dau 30% excess, 50%. 
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1.3.2 Early in vitro studies 
 
Cytotoxicity and cellular uptake of the conjugates were analyzed at University of Cologne by PhD 
Student Lucia Feni, while binding affinity was assessed in University of Milan; these have to be 
considered only preliminary results as further biological analysis are still ongoing. 
- Binding affinity  
Conjugates (16 and 17, Table 2) containing the targeting moiety c[DKPf3-RGD] integrin ligand 
15, and controls (9 and 15, Table 2) were evaluated by Dr. Daniela Arosio (CNR-ISTM, Università 
degli Studi di Milano) for their binding affinity towards the isolated αvβ3 and αvβ5 integrin 
receptors. This test measured the ability of the conjugates to inhibit the binding of biotinylated 
vitronectin to the purified αvβ3 and αvβ5 receptors in a competitive binding assay. The immobilized 
integrin receptor (αvβ3 or αvβ5) was incubated with solutions of the conjugates (16 and 17) and 
controls (9 and 15) at different concentrations in presence of biotinylated vitronectin (1 µg mL-1), 
then the bound vitronectin was measured. The half-maximal inhibitory concentrations (IC50) are 
presented in Table 2. 
 
Code Conjugates and controls IC50 [nM] 
αvβ3 
IC50 [nM] 
αvβ5 
9 c[DKP3-RGD] 4.5 ± 1.1 149 ± 25 
15 c[DKPf3-RGD] 26.4 ± 3.7 >5000 
16 c[DKPf3-RGD]-PEG4-Aoa=Dau 14.0 ± 1.6 6300 ± 400 
17 c[DKPf3-RGD]- GLFG-Aoa=Dau 5.8 ± 0.6 2100 ± 100 
 
Table 2 Inhibition of biotinylated vitronectin binding to αvβ3 and αvβ5 receptors of conjugates and controls. 
 
The two conjugates 16 and 17 retained a good binding affinity for the αvβ3 receptor with IC50 values 
in the nanomolar range. Furthermore, data reported in Table 2 showed that the selectivity towards 
αvβ3 receptor is also retained for all the conjugates tested; in fact the IC50 values for the αvβ5 
receptor are in the micromolar range. 
 
- MTT-based cytotoxicity assay 
Cytotoxicity was evaluated on U87 (human glioblastoma, αvβ3 +) and HT-29 (human colorectal 
adenocarcinoma, αvβ3 -) cell lines, through MTT-based assays by Lucia Feni, working under the 
supervision of professor Ines Neundorf (University of Cologne, Germany).  
U87 (αvβ3 expressing cell line) and HT-29 (αvβ3 non expressing cell line) were treated with different 
concentrations of the conjugates for 72 hours with washout. Cells were washed after 6 hours of 
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incubation, the media was replaced and then the cells were incubated for other 66 hours. This 
procedure has been used intending to simulate the in vivo conditions where the administered 
prodrug is rapidly cleared from the tumor extracellular environment. In this way the conjugates 
degraded or unbound to the integrin receptors are removed from the medium, minimizing the effect 
of metabolites produced by extracellular cleavage of the linker. The cell viability was quantified by 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. 
Cytotoxicity data are reported in Figure 21. The cytotoxicity of the congiugate which presents also 
a cell penetrating peptide (for CPP see paragraph 1.4.1) between our targeting moiety c[DKPf3-
RGD] and Dau, (conjugate 19, Figure 20 synthesized by Lucia Feni) was also reported (graph A, 
Figure 21). The CPP used was the so called sC18 (previously developed by Neundorf’s group83) 
and it was inserted with the aim to enhance the cellular uptake of the peptide.  
All the three conjugates showed enhanced cytotoxicity towards U87 cells compared to HT-29 cells; 
this is much more evident for conjugate 19 (c[DKPf3-RGD]-PEG4-sC18(Lys13-Aoa=Dau) which is 
more effective in U87 cells compared to our conjugates which did not have sC18, 16 (graph B) and 
17 (graph C). In conclusion, the targeting moiety is essential for the selectivity towards αvβ3 for all 
the conjugates tested, and the presence of a cell penetrating peptide is important to improve 
cytotoxicity, likely due to the increased propensity to enter cells.  
 
 
Figure 20: Conjugate 19 (c[DKPf3-RGD]-PEG4-sC18(Lys13-Aoa=Dau) synthesized by PhD student Lucia Feni, 
Neundorf’s group, University of Cologne. 
 
 
 
Figure 21 MTT-based cytotoxicity assay on U87 (αvβ3 +) and HT-29 (αvβ3 ˗) cells of the peptide-drug conjugates 19, 
16 and 17. (15 min incubation with the peptides, then washout and measure after 72h). 
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- Cellular uptake 
The amount of conjugate which is actually internalized by the cells was measured through cellular 
uptake studies. In the case of all our conjugates, the fluorescent properties of Dau were exploited. 
Data relative to conjugate 16 and 17, together with conjugate 19, are reported in the graph in 
Figure 22. After 30 min incubation of both U87 (αvβ3 +) and HT-29 (αvβ5 -) cells with the 
conjugates, the fluorescent intensity was measured. All the conjugates showed a significantly lower 
uptake for HT-29 cells, so once again the selectivity of our conjugates was confirmed. Notably, the 
presence of the cell penetrating peptide in conjugate 19, allowed a much more important uptake. 
 
 
Figure 22 Cellular uptake for the conjugates 16, 17 and 19. Cellular uptake ratios (U87/HT-29): 4.7 for compound 19, 
4.5 for compound 16 and 4.9 for compound 17. 
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1.4 Paclitaxel conjugates  
1.4.1 Cell Penetrating Peptides (CPPs) 
 
One major problem with drug candidates is their low membrane permeability which dramatically 
interfere with systemic drug distribution. This problem is related to the drug’s hydrophilic nature, 
which is, on the other hand, necessary for drug administration. In most cases, good cell uptake is 
then reached raising the administrated drug’s quantities, leading to dramatic side-effects on healthy 
tissues. This is much more true in the case of neurodegenerative diseases; drugs have to cross the 
blood-brain barrier to pass from vasculatures into the parenchyma of the nervous system which has 
exactly the opposite aim to prevent this passage. It is then obvious the necessity to improve the 
translocation process of drugs across the cell membrane. 
Cell penetrating peptides (CPPs) are short peptidic sequences (typically no more than 30 residues) 
which can ubiquitously cross cell membranes in energy dependent/independent manners without 
showing toxicity and without apparent recognition of any receptors.84 
In 1991, Joliot and co-workers demonstrated that a transcription factor of Drosophilia 
melanogaster (the peptidic homeodomain of Antennapedia), regulated neuronal morphogenesis 
after entering neurons.85 Three years later, Derossi et al. identified the basic domain, corresponding 
to the third helix of the Antennapedia homeodomain, bearing the translocation properties; the 16-
amino-acid peptide was named as penetratin (sequence RQIKIWFQNRRMKWKK).86 In the same 
manner, the trans-activator of transcription (TAT, sequence RKKRRQRRR) protein of HIV-1 was 
demonstrated to be efficiently internalized by cells in vitro.87 
 
 
- Classification and uptake mechanisms 
Although the uptake mechanisms by which CPPs internalize is a not well known chapter of this 
story, it is possible to do some considerations; physical-chemical properties of CPPs, cell type and 
cell membrane constitution are driving force in choosing the uptake mechanism.88 Cationic CPPs 
(as TAT and penetratin) show concentration-dependent uptake mechanisms and the formation of 
electrostatic interactions with the phosfolipid bilayer is the first step for cellular entry in most 
cases. Amphipathic CPPs need to assume a helical secondary structure to enter, exposing the 
hydrophobic face to the membrane and the hydrophilic face to the solvent.88  
Anyway, nonendocytic or energy-independent and the endocytic pathways are the two most 
important cellular uptake mechanisms of CPP.89 
Endocytosis is a process which naturally occurs in cells. It consists in the endocytic entry and the 
subsequent endosome escape to avoid lysosomally degradation.89,90 Endocytosis can be mediated 
by Caveolae, Clathrin or it can happen through macropinocytosis (Figure 23).91 
Notably, cells recycle the entire cell surface one to five times per hour trough internalization.88,92 
This continuous internalization should enable peptides, which can easily interact with cell 
membrane, to enter the cell through endocytic pathways.88 
Direct translocation across the cell membrane foresees an energy and temperature-independent 
destabilization of the membrane. Inverted micelles formations and pore formation are only 
hypothesis to explain direct translocation mechanism.89–91 
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Figure 23. Mechanism of peptide uptake through cell membrane. Adapted from ref 92. 
 
- CPPs as delivery systems 
CPPs were used as vectors for siRNA93, small molecules, proteins or other peptides94, both in 
vitro95 and in vivo96. More interesting for the aim of this thesis are CPPs as drug delivery systems.  
The conjugation of drugs with CPPs can be a valuable way to overcome multi-drug resistance and 
toxicity in tumor therapy.97 Improved activity has been detected when diverse chemotherapeutics, 
such as Taxol98, Methotrexate99, and Dox100 where linked to CPPs. Some of these drug delivery 
systems are shown in Table 3. 
In 2013, Duong and co-workers developed the drug delivery system based on synergic properties 
of DOX and PTX as drugs, a folate targeting moiety (folate receptors are overexpressed on the 
surface of different cancer cells) and the CPP TAT peptide.101 Their system showed an improved 
efficacy with respect to the unfunctionalized single drug-loaded micelles (IC50 value of 0.172 μM 
D/0.043 μM P, with respect to the IC50 value of 3.873 μM for D-micelles and 0.790 μM for P-
micelles). CPPs can also incorporate a functional motif and have cytostatic and cytotoxic effect.102 
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Table 3 . Examples of CPPs in anticancer drug delivery. Adapted from ref. 100 
 
Drug targeting is also essential in order to minimize the effects of the drug on healty cells. Drug-
carrier conjugates bearing small molecules, RGD peptides, antibodies etc. have been used to direct 
the drug on the membrane of cancer cells. However, the theoretical effectiveness of these 
conjugates was not demonstrated in 
practice as many factors need to be 
discussed further; the lack of 
understanding about the 
pharmacokinetic profile of the 
conjugate, the appropriate ligand 
and the uptake mechanism are some 
important aspects.103 
Hypothetically, if the delivery of 
the drug carrier conjugate is done 
through parenteral routes, the 
conjugate reaches the target via the 
systemic circulation. A possible 
mechanism of internalization can be 
as the one represented in Figure 24. The conjugate may undergo receptor mediated endocytosis, 
after targeting the receptor. The conjugate then pass to the early and the late endosome and finally 
to the lysosome. The receptors will be restored on the surface. The drop of the pH inside the 
lysosomes may affects the linkage between the drug and the peptide.103 
 
  
Figure 24. Hypotetical mechanism of internalization of a peptide-drug 
conjugate. Adapted from ref 106 
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- CPP-drug conjugation strategies 
Different strategies can be used in order to link the drug to the CPP, depending on the chemical 
characteristics of both, drug and CPP. Of course, the choice of the right conjugation procedure  
is essential just because it can affect several aspects including the mechanism of entry in the cell, 
the route of administration of the construct or, banally, the availability of the drug inside the 
cells.91,103 In the majority of the cases, a covalent linkage is used in the CPP-drug constructs both 
stable or cleavable linkages. In 2012, Wender et al. conjugated the CPP R8 (octaarginine) to the 
Taxol through a disulfide linkage which is cleaved in the reducing conditions of the cytosol, thus 
releasing there the free drug.104 Oxime linkage was used by Lelle et al. to link the R8 with DOX.105 
In another work, sC18 was linked through amide bond to Cymantrene by Splith et al.106  
 
- Cationic antimicrobial peptides  
Cationic antimicrobial peptides (CAMPs) are short amphiphilic peptides (12 - 50 amino acids) 
bearing basic amino acids (arginine, lysine and histidine) in a big amount such that they are 
characterized by a net positive charge (+2 to +7) and with approximately 50% of hydrophobic 
amino acids. Although their relative small length, they are mostly found assuming tertiary structure 
as β-sheet, α-helices or loops. The mechanism of action foresees the disruption of the membrane bi-
layer in a detergent-like manner, as a consequence of their accumulation on the membrane itself, 
folding in amphiphilic conformations when interacting with the negatively charged membrane 
phospholipids, leading to pore formation.107 They were initially found to modulate innate host 
defence as they are mostly produced at site of inflammation or infections in all leaving species as 
immediate non-specific defence.108 Their properties make them good candidates in therapeutic 
anctibacterial use109, but some recent studies demonstrated their utility also in cancer biology.110,111 
Two biggest groups of antimicrobial peptides are present in humans: defensins and cathelicidins. 
Defensins contain six cysteine residues which are highly conserved although the variability in the 
sequences. Cathelicidins have a conserved N-terminal domain, known as the cathelin domain, and a 
C-terminal domain bearing the antimicrobial properties. In humans, the precursor protein has a 
mass of 18 kDa therefore it is named hCAP18.107,110  
 
1.4.1.1 sC18 as CPP  
In 1994, Tossi and co-workers112 identified the primary antibacterial domain in the 
lipopolysaccharide binding protein CAP18. Highly cationic sequence in its C-terminal domain 
(named C18, 106GLRKRLRKFRNKIKEKLKKI125) was identified as responsible of CAP18’s 
antimicrobial properties due to the tendency to adopt an amphipathic α-helical conformation. In 
fact, disruption of the helix possibly eliminates the antibacterial activity toward both Gram-
negative and Gram-positive bacteria. Based on these considerations and taking into account the 
sequence analogy between Tat (48GRKKRRQRRRPPQ60) peptide and the C18 fragment, Neundorf 
et al. hypothesized that a shorter analogue of CAP18, residues 106-121, named sC18 (sequence: 
106GLRKRLRKFRNKIKEK121) still maintained the CPPs’ properties (same number of Arg and Lys 
residues as in Tat peptide).83 They actually demonstrated, by flow cytometry analysis, that the new 
CPP sC18 and Tat had a comparable internalization efficiency. In addition, circular dichroism 
studies showed the tendency of sC18 to adopt α-helical structure which was in agreement with that 
reported for the parent C18.  
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In 2012, Hoyer et al.113 demonstrated that dimeric version of sC18 enhanced cellular uptake in 
different cell lines, but also increased cytotoxicity in some cases. They also demonstrated the 
ability of the sC18 to carry cytostatic compounds such as Cymantrene and Chlorambucil into tumor 
cells, notably increasing their therapeutic potential. 
It was further shown that a shortened version of sC18 (sC18*, 106GLRKRLRKFRNK117) also has 
cell penetrating capabilities.114 
 
1.4.2 Synthesis  
 
Synthesis of the PTX conjugate was planned in both solid and solution phase. Three main building 
blocks were considered: 
-the targeting moiety with the PEG-4-N3 spacer (c[DKPf3-RGD]-PEG-4-N3)  
-sC18 bearing the cysteine linked to Lys13 through β-alanine spacer (sC18 branched) 
-PTX connected to the maleimide moiety through the self-immolative linker 
The targeting moiety c[DKPf3-RGD]-PEG-4-N3 34 was synthesized as described in Scheme 3. 
 
 
- Synthesis of sC18 branched peptide (45) 
Synthesis of the CPPs sC18 was done using Solid phase peptide synthesis115 (SPPS). In SPPS, the 
synthesis of peptides is carried out on a solid resin support, while unreacted reagents and by-
products are simply removed via washing as the growing peptide chains remain attached to the 
resin. In this way, purification of peptide intermediates is redundant and the whole process can be 
carried out in one single reaction vessel. Furthermore coupling cycles are shorter than in traditional 
peptide synthesis. This simple procedure also allows for automatization, making possible, in a short 
time, parallel synthesis of different and long peptides. The Nα-group of every amino acid and side 
chains are blocked by a protecting group to avoid unwanted side-reactions. The amino acid’s 
carboxy group must be activated since it is not sufficiently electrophilic for coupling to proceed. 
Carbodiimides are often employed as activators but their use can lead to racemization.116 Therefore 
the use of racemization suppressants, such as HOBt, or its non-explosive alternative Oxyma, which 
traps intermediates prone to racemization and forms the activated species is necessary.117 Finally, 
the peptide is fully deprotected and cleaved off the resin support. Crude peptide sample must be 
purified to remove side-products lacking one or more amino acids considering that aminoacylation 
is not quantitative.118 
Fmoc/tBu strategy was adopted for the sC18 synthesis; α-amino groups were protected by the base-
labile Fmoc group and side-chains were protected by tBu or other acid-labile groups in order to 
ensure the complete orthogonality. The peptide sequence sC18 (106GLRKRLRKFRNKIKEK121) 
was synthesized on a Rink-amide resin (Fmoc-L-Lys(Boc)-Rink Amide, 0.015 mmol scale) by 
automated multiple solid-phase peptide synthesis (aSPPS) using a robot system. 
The synthetic strategy is reported in Scheme 6. As previously mentioned, the peptide was 
synthesized on Rink Amide resin mainly by aSPPS starting from the C-terminal amino acid. 
Lys13 was coupled manually as Fmoc-Lys(DDe)-OH, then the peptide was again elongated by 
automation. The N-terminal Gly106 was replaced by propargylGly as the targeting moiety c[DKPf3-
RGD]-PEG-4-N3 is then linked via the copper catalyzed alkyne-azide cycloaddition (CuAAC). 
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After selective cleavage of Dde protecting group on Lys13 using hydrazine in DMF, Fmoc-β-Ala 
and Fmoc-Cys(Trt)-OH were sequentially coupled manually to the resin (using a double coupling 
step, HATU, DIPEA and Oxyma, DIC). After Fmoc deprotection on Cys, peptide 45 was cleaved 
from the resin using a mixture of H2O/TIS/TFA 2.5:2.5:95. Pure peptide 45 was obtained after 
HPLC purification in 63% yield. 
 
 
 
 
Scheme 6 Synthesis of the sC18 peptide (45). Reagents and conditions: a) Fmoc-Lys(Dde)-OH, Oxyma, DIC, DMF, 2 h, 
r.t.; b) 1) Fmoc-Pra-OH, Oxyma, DIC, DMF, 2 h, r.t., 2) 20% piperidine in DMF, 45 min, r.t., 3) Boc2O, DIPEA in 
DCM; c) 1)3% hydrazine in DMF, 2) Fmoc-β-Ala-OH, Oxyma, DIC, DMF, 2 h, r.t.; d) 1) 20% piperidine in DMF, 45 
min, r.t., 2) Fmoc-Cys(Trt)-OH, Oxyma, DIC, DMF, 2 h, r.t.; e) 1) 20% piperidine in DMF, 45 min, r.t., 2) H2O/TIS/TFA 
2.5:2.5:95. 3h, r.t., 63%. 
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- Synthesis of maleimide-Val-Ala-PAB-diamine-PTX 
First of all Paclitaxel was activated at 2’-OH position with 4-nitrophenylchloroformate in presence 
of pyridine in DCM (46, Scheme 7). 
 
 
Scheme 7 Synthesis of 2’-(4-Nitrophenoxycarbonyl)paclitaxel (46). Reagents and conditions: a) p-nitrophenyl 
chloroformate, pyridine, THF, 0°C to r.t., 55%. 
 
Synthesis of maleimide-Val-Ala-PAB-diamine-Ptx (54) is still ongoing and it was planned as 
described in Scheme 8. The lysosomally cleavable linker Val-Ala containing the p-aminobenzyl 
alcohol (PABA) self-immolative spacer was prepared following the procedure of Kratz and 
coworkers.119 The synthesis was carried out in solution starting from commercial Fmoc-Val-OH 
(47) which was activated with NHS and DCC (1:1) in THF. The latter was then coupled to free 
alanine using NaHCO3 as a base in a mixture water/THF/diethyl ether to obtain Fmoc-Val-Ala-OH 
(48) in 93% yield. P-aminobenzyl alcohol reacted with the dipeptide 48 in a mixture of 
DCM/MeOH 2:1, using EEDQ as coupling agent to avoid racemization, giving Fmoc-Val-Ala-
PABOH 49 (78%). The hydroxy group of 49 was activated with p-nitrophenyl chloroformate in 
THF, using pyridine as HCl scavenger, to afford the activated linker Fmoc-Val-PAB-PNP 50 in 
66% yield. Compound 50 was then let to react with N-Boc- N,N’-dimethylethilendiamine in THF, 
in presence of DIPEA, yielding Fmoc-Val-PAB-PNP-diamine 51 in 74% yield. Fmoc- deprotection 
of 51 was carried out in solution with piperidine in DMF, avoiding the isolation of the free amine. 
Indeed, after piperidine removal, the crude amine was treated with glutaric anhydride affording 
compound 52. After activation of the carboxylic group in 52 with DIC and NHS, N-(2-
aminoethyl)maleimide-TFA salt was coupled obtaining the bifunctional linker 53 (55%). The rest 
of the synthesis is still ongoing. We planned to link the activated PTX (2’-(4-
Nitrophenoxycarbonyl)paclitaxel 46) to the linker 53, using DIPEA, HOAt in DMF, to afford the 
maleimide-Val-Ala-PAB-diamine-PTX 54. 
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Scheme 8. Synthesis of maleimide-Val-Ala-PAB-diamine-Ptx (54). a) DCC, NHS, THF, 0°C to rt. overnight; b) Alanine, 
NaHCO3, THF/diethyl ether/water 1:1:1, r.t., 4 days, 48% over two steps; c) p-aminobenzyl alcohol, EEDQ, 
DCM/MeOH 2:1, r.t. 48 h, 78%; d) p-nitrophenyl chloroformate, pyridine, THF, 0°C to r.t., 4h, 66%; e) N-Boc- N,N’-
dimethylethilendiamine, DIPEA, THF, overnight, 74%; f) 1) piperidine DMF, 2h; 2) glutaric anhydride, DMAP, DIPEA, 
DMF, overnight, 89% over two steps; g) 1) DIC, NHS, DMF, on; 2) N-(2-aminoethyl)maleimide-TFA salt, DIPEA,, 55% 
over two steps; h) reaction ongoing, 1) TFA in DCM; 2) 2´-(4-nitrophenoxycarbonyl)PTX, DIPEA, HOAt, DMF, 24h. 
 
As the last step of the previous synthetic pathway, the last two steps of the final conjugate’s 
synthesis (Scheme 9) are ongoing. They consist in two click reactions; the thiol-maleimide click 
reaction and the CuAAC reaction with the c[DKPf3-RGD]-CH2NH2-PEG-4-N3, yielding final 
conjugate 18. 
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Scheme 9. Synthesis of the conjugate sC18-c[DKPf3-RGD]- Val-Ala-PAB-diamine-Ptx 18. a) PBS (pH=7), ACN, r.t., 
1h; b) Sodium ascorbate, CuSO4.5H2O, tert-buthanol/H2O 1:1, o.n. 
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1.5 Conclusions and outlooks 
With the aim of synthesizing small molecule drug conjugates bearing the potent integrin ligand 
c[DKPf3-RGD], previously developed by our group, two new Daunomicin conjugates (16 and 17) 
were synthesized and characterized. In addition, a conjugate bearing the CPP sC18 (19) was 
synthesized in collaboration with Neundorf’s group (University of Cologne). In conjugate 16 the 
targeting moiety was linked to the drug (Dau) through a PEG-4 spacer via a dipeptide Propargyl-
glycine-aminooxyacetic acid in order to insert an uncleavable linker. On the other hand, conjugate 
17 show the protease cleavable linker GFLG linked to the Dau through oxyme linkage with 
aminooxyacetic acid, while the targeting moiety is linked through a simple amide bond. 
Preliminary biological studies were conducted both in University of Cologne and University of 
Milan. Conjugates 16 and 17 were tested in vitro to determine their ability to inhibit the binding of 
biotinylated vitronectin to the purified αvβ3 and αvβ5 receptors in a competitive binding assay. They 
retained a good binding affinity for the αvβ3 receptor with IC50 values in the nanomolar range and a 
selectivity towards αvβ3 receptor. The importance of their selectivity was also remarked by 
cytotoxic assays and cellular uptake. The presence of the sC18 in conjugate 19 demonstrated the 
great potential of the use of a CPP to increase uptake and thus, cytotoxicity. More in-depth 
biological analysis and also further analysis (for example serum stability) are currently ongoing. 
Synthesis of an additional conjugate (18) bearing our integrin targeting moiety, a cell penetrating 
peptide and Paclitaxel as cytotoxic payload was planned. Cell penetrating properties of sC18 were 
exploited to improve the CPP-mediate internalization of the entire conjugate and in consequence 
enhance cytotoxicity. The presence of a self-immolative spacer (PABC-N,N’-di-
methylethylenediamine) and a lysosomally cleavable dipeptide linker (Val-Ala), was chose in order 
to have Ptx releasing as free drug inside the cell. The synthesis of the three building blocks was 
almost complete, the last steps are missing. Once the conjugate will be ready, it will be tested for 
its ability to penetrate cell membrane (cellular uptake) and for its cytotoxicity. 
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2 New DKP-based peptidomimetic inhibitors of cadherin 
homophilic interactions 
 
 
2.1 Cadherins 
 
Cadherins are transmembrane proteins involved in diverse fundamental cellular processes including 
cell-cell adhesion, cell recognition and signalling. Cadherin binding is usually homophilic, so that 
adhesion via cadherins is an intercellular adhesion. Differently, integrins and proteoglycans are 
involved in cell–matrix as well as cell–cell interactions. However, a heterotypic interaction 
between E-cadherin and the integrin αEβ7 was reported in 1998120; the involvement of cadherins in 
cell–matrix interactions on artificial substrates, coated with the extracellular domain of cadherins 
was also demonstrated.121,122  
 
- Families 
Hundreds human cadherins have been identified and classified into three families: major cadherins 
(CDH), protocadherins (PCDH) expressed primarily in the nervous system, and cadherin-related 
proteins (CDHR). Epithelial cadherin (E-cadherin) is the progenitor member in cadherin 
family.123,124 Its N-terminal domain (extracellular domain) was determined by NMR studies in 
1995.125 In the same year, the first crystal structure of the murine Neuronal cadherin (N-cadherin) 
domain was solved by Shapiro et al.126 Since then, lots of cadherin structures were studied and 
listed.123,124 
Another classification provides for the distinction of type I (classical) and type II cadherins linked 
to the actin cytoskeleton, on the bases of sequence homologies.127 
 
- Structure and mode of action 
Cadherins are transmembrane glycoproteins composed by five extracellular domains arranged in 
tandem and linked via calcium ions, and a cytoplasmic domain normally associated with some 
cytoplasmic proteins (Figure 25). The N- and C- 
termini of the cadherin protein chain are located outside 
and inside the cell, respectively. The N-terminal region, 
or ectodomain, consists of a variable number of highly 
conserved sequences which are repeated in the 
extracellular domain. Classical cadherins contain five 
extracellular domains that are commonly known as 
EC1- EC5. The conformational stability and the 
capacity to mediate cell-cell adhesion of the cadherin is 
ensured by the presence of Ca2+ ions located between 
neighboring extracellular domains. The presence of 
Figure 25: Cadherin structure. Adapted from ref 133. 
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Figure 26 Swap dimer. Adapted from ref 
136 
Ca2+ is necessary for cadherin adhesive function and, it is no accident that their name is the 
contraction of ‘calcium-dependent adherent protein’.128,129 
The cytoplasmic domain of classical cadherins is normally associated with catenin and actin 
filaments. The cadherin–catenin complex is necessary for providing cell–cell adhesion.130 This was 
also confirmed by the fact that recombination or deletion of specific portion in the cytoplasmic 
domain significantly affects the formation of cadherin-catenin complex and the proteosomal 
degradation of cadherin.131 Already in 1988, Nagafuchi and Takeichi demonstrated that the 
cytoplasmic domain is essential for providing normal cell-cell adhesion.132. 
In the last years, different studies were conducted to elucidate the cadherin-mediated adhesion 
mechanism. Some studies on type I cadherins are in agreement with 
the formation of a “swap dimer”. The N-terminal β-strand from the 
EC1 domain of each paired cadherin exchanges with that of the 
partner molecule; the six-residue-long N-terminal portion of the 
protein, usually referred to as the “adhesion arm” (DWVIPP in E- 
and N-human and mouse cadherins) is positioned in an “acceptor 
pocket” of the other cadherin, to form the trans homodimer (Figure 
26).133,134 The presence of a conserved Trp in position 2 on the 
adhesion arm, which is accommodated into the hydrophobic 
acceptor pocket, was established. In addition, some other conserved 
interactions were depicted, as reported in the Figure 27: a salt 
bridge between the N-terminal Asp1-NH2 and carboxyl group of 
Glu89 as well as the hydrogen bond between Trp2 and the carbonyl 
group of Asp90.133 
Another interaction is established among the planar carboxyl group 
of Glu89 and the aliphatic side chain of Met92 from the acceptor 
pocket onto the pyrrole ring of the Trp2.133 
This is consistent with that found in numerous other structures of adhesive type I and type II 
ectodomain fragments.126,128,134 
 
 
Figure 27 Interaction between the N-terminal part (bearing the Trp2) of the magenta cadherin and the hydrophobic 
acceptor pocket of the green cadherin forming the “swap dimer”. Adapted from ref. 136. 
 
The crystal structures of the complete ectodomains of N- and E-cadherin were studied and 
compared with the previously determined structure of C-cadherin.128 The three crystals have in 
common the well-characterized trans strand swap adhesive interface between EC1 domains, and a 
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lateral cis interface in which a different EC1 domain interacts with the EC2 domain of a 
neighboring cadherin (Figure 28).134 
 
 
Figure 28 Structure formed by cis interactions between parallel ectodomain in N-cadherin. Adapted from ref 137 
 
Proper amino acid mutations, in the human E-cadherin, were introduced at the cis interface level in 
order to determine their role in the adhesion mechanism; the mutations resulted in loss of ability to 
form cell-cell junctions; indeed, the combination with the trans interactions produces stable 
structures, but cis interactions are not on their own able to produce observable adhesive structures 
on an isolated cell surface.134 So, the adhesive junction formation is the result of cooperativity 
between cis and trans interactions.135 
Interestingly, domains EC1–EC5 have an extra residue near their N terminus, usually Pro, that 
inserts into the hydrophobic pocket of its domain, in order to do not strand swap. However, in 
isolated EC1, and in domains EC2–EC5, Trp2 inserts into the corresponding pocket in its own 
domain. In the type II cadherins, Trp4 is also highly conserved and it participates in swapping 
interactions.136 
A model for the binding mechanism of type I cadherins was proposed by Parisini et al.133 and it is 
shown in Figure 29. Cadherins are synthesized as an inactive forms in which the adhesion arm 
lacks of a free N terminus so the salt bridge with Glu89 is not formed. The adhesion arm can fit in 
the hydrophobic pocket of EC1 only after proteolytic activation. Intercalation of Trp2 is stabilized 
by a stacking interaction with Glu89 and Met92, and the formation of the salt bridge between 
Glu89 and the now free N-terminal amine. However, an equilibrium exists between the closed and 
the opened form in which the adhesion arm is dissociated from the body of EC1. The adherents 
junctions is formed when the open adhesion arm is stabilized by binding to an opposing cadherin, 
creating swap trans dimers through inter-molecular docking of Trp2 and salt bridge formation.133 
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Figure 29 Proposed mechanism for the swap dimer formation. Adapted from ref 136 
A very similar mechanism was found for type II cadherins; cadherin-11, cadherin-8 and MN-
cadherin were studied from the crystallographic point of view.137 The adhesive interaction is again 
confined to the EC1 domains. However, in type II cadherins, the side chains of Trp2 and Trp4 of 
the swapped strand, insert into a larger pocket in the hydrophobic core of the partner molecule. 
Notably, the structural features of type II and type I cadherins suggest that members of one family 
are not compatible as binding partners for members of the other family. In other words, binding 
specificities of type I cadherin are orthogonal to the ones of type II cadherin 137,138  
Anyway, the cadherin dimerization pathway, leading from the monomer to dimer formation, is 
highly dynamic as it involves different intermediate steps. Indeed, it has been showed that 
cadherins pass through an intermediate dimeric state known as “X-dimer”; it is kinetically 
important in the dimerization of classical cadherins by lowering the energy barrier of the adhesive 
mechanism.139 The X-dimer of the P-cadherin was isolated and characterized and it was found that 
the monomeric P-cadherin dimerizes only after stabilization by Ca2+ between the EC1 and EC2 
domains (Figure 30).140 
 
 
Figure 30 Mechanism of X-dimerization. Adapted from ref 143 
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- Cadherins and cancer 
A great variety of studies have shown the existence of a connection between cancer progression 
and dysregulation of cadherins.141 It has been demonstrated that neuronal and vascular endothelial 
cadherin (VE-cadherin) play a key role during blood vessel formation and that N- and osteoblast 
cadherin (OB-cadherin) promote cancer cell metastasis; in this sense, N-, VE- and OB-cadherin can 
be seen as target for anticancer therapy.142 However, E-cadherin represents the most interesting 
subject in the involvement of the cadherin family in drug resistance, angiogenesis, cancer cell 
invasion, and metastasis and hence in cancer progression. The relationship between E-cadherin 
dysfunction and cancer progression has been identified in the fact that epithelial tumor cells often 
lose E-cadherin as they became metastatic.141 Indeed, E-cadherin acts as a suppressor of invasion 
and metastasis potentially in the regulation of β-catenin signalling, in the inhibition of mitogenic 
signalling through growth factor receptors and in the possible determination of epithelial polarity. 
143
 
E-cadherin has been addressed as a tumor suppressor in various adenocarcinoma, such as lung, 
laryngeal, colorectal, gastric, prostate, and pancreatic cancer as reviewed by Birchemeier and 
Behrens in 1994;144 one reason was that E-cadherin inhibits epithelial-mesenchymal transitions 
(EMT).145 
However, more recent studies support the idea that E-cadherin is important for disease progression 
in some cases. The case of the ovarian cancer is particularly interesting; tumor proliferation is 
improved through E-cadherin by activation of the protein kinase (MEK/ERK) pathway in 
development of ovarian epithelial cancers as reported in 2012 by Dong et al.146 
Anyway, cadherins and their regulators can become valuable potential therapeutic targets.  
 
2.1.1 Peptidomimetic ligands to cadherins 
 
The rational design of ligands targeting cadherin protein-protein interactions is still in its early 
days. Since Shapiro et al.126 in 1995 highlighted the contribution of the HAV (His89-Ala80-Val81) 
and INP (Ile53-Asn54-Pro55) sequences to the cadherin-mediated adhesion mechanism, libraries of 
peptide and non-peptide molecules mimicking this sequence were developed in order to inhibit the 
dimerization process.147,148 The HAV and INP motifs are part of the extracellular domain 1 (EC1), 
which was demonstrated to take part in the adhesion mechanism of type I cadherins. The 
importance of the residues flanking the HAV motif, in developing small peptides antagonists of N-
cadherin, was also determined.149 N-cadherin is a potential target for anticancer therapy also 
because cancer progression is often characterized by the ‘cadherin switch’ from epithelial E to 
mesenchymal N cadherins; the downregulation of E-cadherin and the over-expression of N-
cadherin would lead to the transition from a benign to a malignant cancer phenotype.150 
Peptide named ADH-1 (Figure 31) with the formula N-Ac-CHAVC-NH2 was developed by 
Adherex Technologies Inc. as antagonist of N-Cadherin. It has been shown to inhibit angiogenesis 
but, up to now, it has been subjected to few clinical trials.151 ADH-1 was demonstrated not to have 
an effect on normal vasculature; indeed its toxicity at the doses tested in animals152 and humans153 
was low. Ovarian cancer might be successfully treated using ADH-1.153 Clinical trials performed 
using ADH-1 in combination with melphalan have shown very promising results in the treatment of 
melanoma.154 
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Figure 31 Structure of ADH-1 or Exherin 
 
2.1.2 First generation DKP-based peptidomimetics 
 
The first library of peptidomimetics based on the N-terminal “adhesion arm” (1DWVI4, Asp-Trp-
Val-Ile) of N- and E- cadherin was reported in 2015.155 The library comprises peptidomimetics 
with the general formula NH3+-Asp-scaffold-Ile-NHR bearing different conformationally 
constrained scaffolds and a benzyl moiety, in order to mimic the Trp2 pose of the native N-terminal 
sequence. These peptidomimetics were first designed using a docking protocol on a model of the 
EC1 fragment of N- and E- cadherin; the best candidates (Figure 32) were then selected 
considering their matching with the main binding interactions. All the three ligands form the salt 
bridge between the N-charged Asp1 of the N-terminal and the side chain carboxylate of Glu89 and 
insert the benzyl ring in the hydrophobic pocket of Trp2. Anyway, only structures 57 and 58 
reproduce the backbone conformation of the native sequence. The ligands were synthesized and 
their ability to inhibit cadherin binding was tested on EOC cells (N-cadh-expressing EOC cell line 
SKOV3 and N-cadh-Fc chimeric protein).155 Inhibition of N-cadh homophilic bynding by ligands 
57 and 58 at 2 mM was  
78% and 84%, respectively, and 50% and 65% at 1 mM concentration. At 2 mM concentration 
ADH-1 and 56 provided about 50% inhibition of N-cadh-Fc/cells interactions and appeared nearly 
ineffective at 1 mM concentration (Figure 33). Conversely, when tested on the E-cadh-expressing 
EOC cell line OAW42, at the concentration of 2 mM 56 and 58 gave about 50% inhibition of E-
cadh-Fc binding to the cells while ADH-1 showed 30% inhibition, indicating a slightly better 
efficacy compared to ADH-1 in inhibiting also E-cadh homophilic interactions.155 
In conclusion, compounds 57 and 58 were found to be effective in inhibiting N-cadh homophilic 
and, in slightly lower extent, also E-cadh homophilic adhesion. 
 
 
Figure 32 Peptidomimetic ligands with the general formula NH3+-Asp-scaffold-Ile-NHR, 56-58. 
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From the chemical point of view, ligands 57 and 58 are particularly able to mimic the conformation 
of the native sequence DWVI through the presence of the diketopiperazine (DKP) scaffold which 
replaces the central dipeptide Trp2-Val3 unit of the DWVI sequence.155 
In fact, DKPs represent privileged structures for drug discovery.156 Reducing the susceptibility to 
metabolic amide bond cleavage and inducing conformational rigidity are the results of constraining 
the nitrogen atom of an α-amino amide into a DKP ring. As reported previously, they can be 
functionalized, from the chemical and stereochemical point. Notably, ligands 57 and 58 differ for 
the stereochemistry at the carbon stereocenter in the DKP ring.  
The library of peptidomimetics discussed, represent the first generation of DKP-based 
peptidomimetics which are able to specifically bind to N-cadherin even in the μM range; in 
particular the ligand 58 is one of the best cadherin homophilic inhibitor reported to date.155 
One year later, Nardone et al.157 published the first crystal structure of human E-cadherin-(Val3)-
EC1EC2 fragment (lacking of the first two amino acids Asp-Trp at the N terminus) co-crystalized 
with ligand 58. The fragment was used instead of the native form, in order to obtain the 
hydrophobic pocket of Trp-2 intrinsically unoccupied and so more easily accessible to the ligand 
58. 
Figure 34 shows the crystal structures of the E-cadh fragment without (A) and with (B) ligand 58; 
the fragment is unable to form the swap dimer because of the lack of the Trp2 so it was found in 
the X-dimer conformation. The ligand binds across the two cadherins and it does not interact with 
the Trp2 pocket (as suggested by previously preliminary studies); in particular, the phenyl ring is 
inserted into a hydrophobic cavity formed by Ile4, Pro5, Ile7, and Val22 residues. This interaction 
was the evidence of an inhibitory mechanism in which the ligand binds across the weakly adhesive 
X-dimer conformation at the level of the two adhesion arms (Figure 35). In the free structure, some 
water molecules occupy the space which is then occupied by the ligand 58 in the ligated form, as 
shown by the electron density map in Figure 36.157 
  
Figure 33 Inhibition of N-cadh binding by the peptidomimetic ligands 56-58 and the inhibition by ADH-1 as 
control. Adapted from ref 158. 
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Figure 34 Crystal structure of E-cadherin-
EC1EC2 fragment in its free form (A) and in 
the presence of the ligand 58 (B). Adapted from 
ref 160. 
Figure 36 Electron density map in the binding region of 
the free structure (A) and in the presence of the ligand 
58 (B). adapted from ref 160. 
Figure 35 Binding interactions of the ligand 58
into the binding region between two fragment
EC1EC2. Adapted from ref 160. 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The binding of the ligand to the intermediate X-dimer is able to block the system at the weakly 
adhesive X-dimer conformation, thus avoiding the formation of the strand dimer. 
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2.2 Second generation DKP based peptidomimetics 
As reported previously, the key interactions formed in the binding pocket during the homophilic 
adhesion are: (i) a salt bridge between the N-terminal Asp1-NH2 and carboxyl group of Glu89, (ii) 
the hydrogen bond between Trp2 and the carbonyl group of Asp90 and (iii) the interaction of the 
key Trp2 with the hydrophobic pocket.133  
Ligands 57 and 58 are able to, (i) form the salt bridge with the Glu89 and (iii) insert the benzyl ring 
in the hydrophobic pocket; but it is clear that they cannot form (ii) the hydrogen bond with the 
Asp90 because the benzyl group is not an HB (hydrogen bond)-donor. 
Identical interactions were depicted for N-cadherin 155 by crystallographic methods as shown in 
Figure 37. 
 
Figure 37 2D representation of the DWVI interactions into the N-cadherin binding site. Adapted from ref 158. 
 
It seems, therefore, obvious the need to improve the ability of the ligand to bind the homophilic 
active site developing the second generation DKP-based peptidomimetics. 
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2.2.1 Aim of the project 
 
The aim of our project is then to improve the first generation ligands by adding a HB-donor group. 
We decided to replace the benzyl group and insert an indolyl moiety on the DKP scaffold aiming to 
fulfill all the key interactions in the homophilic adhesion site. In these way the ligand is much more 
similar to the N-terminal sequence DWVI of the adhesion arm. 
In order to develop the second generation DKP-based peptidomimetic inhibitors of cadherin 
homophilic interactions, docking studies were performed (Prof. Belvisi, Università degli Studi di 
Milano) to identify the best mimics containing the indolyl moiety on the DKP scaffolds. The results 
have shown that to obtain the optimization of the key interactions with E-cadherin the trans-DKP3 
scaffold (59) needs a methyl-indolyl moiety, while the cis-DKP1 scaffold (60) needs the ethyl-
indolyl moiety. 
 
 
Figure 38 Structures of the second generation DKP-based ligand as inhibitors of cadherin interactions: ligand with the 
DKP3 (3S, 6R) scaffold (59) and ligand with the DKP1 (3S, 6S) scaffold (60). 
Furthermore, we planned to synthesize a cyclic ligand for cadherin homophylic interactions, as 
showed below (Figure 39). 
 
Figura 39 Structure of c(DKP3-Gly-Arg-Trp) (61) 
 
We started with the synthesis of the ligand 59 bearing the DKP3-indolyl scaffold. 
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2.2.2 Synthesis of Asp-DKP3-indolyl-Ile (59) 
 
- Synthesis of the DKP3-indolyl scaffold 
The synthesis of the scaffold was planned in solution (Scheme 10) starting from (S)-serine 62 and 
(R)-aspartic acid 19. (R)-aspartic acid β-allyl ester and (R)-N-(tert-butoxycarbonyl)aspartic acid β-
allyl ester 20 were easily prepared according to literature procedure158 as well as (S)-serine methyl 
ester 21.159 Indole-3-carboxaldehyde 63 was Mtr protected at the nitrogen using Mtr-Cl and 
DIPEA, yielding N-indole (Mtr)-3-carboxaldehyde 64 in reasonable yields (44%). The Mtr 
protecting group was chosen because of its orthogonality with the others protecting groups (Boc- 
and Allyl-). (S)-N-indolyl (Mtr) serine methyl ester 65 was prepared via reductive amination with 
N-indole (Mtr)-3-carboxaldehyde 64 using NaBH(OAc)3 as reducing agent; acidic conditions, 
catalytic amount of AcOH, were necessary to accelerate the reaction and to obtain better yields 
(64%).  
(S)-N-indolyl (Mtr) serine methyl ester 65 was then coupled with (R)-N-(tert-butoxycarbonyl) 
aspartic acid β-allyl ester 20, using HATU, HOAt as coupling agents and DIPEA in DMF, to form 
the isopeptide 66 in good yield (around 80%). Notably, the yields were comparable with the ones 
of the coupling between the N-benzylserine methyl ester and the 20 as reported previously.50  
After Boc-deprotection of 66 and cyclization to form the diketopiperazine scaffold DKP3 67, the 
introduction of the azide group was carried out through a Mitsunobu-type reaction. The azido 
derivative 68 was then converted into the NHBoc-compound 69 through one-pot Staudinger 
reduction-Boc protection. De-allylated compound 70 was obtained via Pd(0) catalyzed Tsuji-Trost 
reaction.  
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Scheme 10 Synthesis of DKP3-indolyl scaffold (70). Reagents and conditions: a) CH3COCl, Allyl alcohol, 0-5°C; b) 
Boc2O, TEA, H2O/Dioxane 1:1 (v/v), r.t.; c) CH3COCl, CH3OH, reflux d) Mtr-Cl, DIPEA, dry THF, 0°C then r.t., under 
N2,o.n., 44%; e) NaBH(AcO)3, AcOH, dry THF, r.t., under N2, 64%; f) HATU, HOAt, DIPEA, dry DMF, 0°C to r.t., 
under N2, o.n., 80%; g) 1) TFA/DCM 1:2,0°C then r.t.; 2) DIPEA, iPrOH, r.t., 80%; h) PPh3, DIAD, HN3.tol, dry 
DCM/Tol 4/6, -20°C, under N2, 5h, 88%; i) Me3P in THF, Boc-ON, dry THF, -20°C to r.t., 70%; j) Pyrrolidine, PPh3, 
[Pd(PPh3)4], DCM, quant. 
 
The synthesis of the peptidomimetic ligand of cadherin homophylic interactions (Scheme 11) was 
then continued on the scaffold 70. 
 
- Synthesis of ligand Asp-DKP3-indolyl-Ile (59) 
Boc-Ile-CONHtBu 73 was prepared starting from L-Ile OH 71; first NHBoc protection (72) and 
then amide formation with tert-butyl amine in presence of HOBt and EDC to form the active ester. 
After Boc deprotection to form the TFA salt (74), direct coupling with 70 was accomplished to 
afford 75 in good yield. The amino group of the DKP scaffold was first deprotected from the Boc- 
group and then coupled with Boc-Asp (OtBu)-OH using HATU, HOAT and DIPEA to afford the 
final linear peptide fully protected 76 in 67% yield. 
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Scheme 11 Synthesis of Asp-DKP3-indolyl-Ile-NHtBu (59). Reagents and conditions: a) Boc2O, TEA, H2O/THF 1:1 
(v/v), r.t., 95%; b) HOBt, EDC HCl, tert butylamine, DMF 0°C to r.t., 54%; c) TFA/DCM 1:2,0°C then r.t.; d) 73, 
HATU, HOAt, DIPEA, dry DMF, 0°C to r.t., under N2 o.n., 62% ; e) 1) TFA/DCM 1:2,0°C then r.t; 2) Boc-Asp(OtBu)-
OH, HATU, HOAt, DIPEA, dry DMF, 0°C to r.t., under N2, 67%; f) different conditions, see the text. 
 
The deprotection of the ligand from the remaining protecting groups (Boc- and tBu- on the aspartic 
acid and Mtr- group on the NH-indolyl) was the most challenging step. 
The final deprotection was carried out using first Reagent K160 (82.5% TFA, 5% phenol, 5% H2O, 
5% thioanisole, 2.5% EDT) which is the cleavage cocktail used previously in our group for the 
final deprotection of the cyclic RGD-DKP integrin ligands containing essentially the same 
protecting groups (Boc-, tBu ester-, Mtr-).51 We found that these conditions were not suited in our 
case for the final deprotection; in fact, degradation and in some cases loss of the entire methyl-
indolyl group was detected with no presence of the fully deprotected ligand. We also tried to use 
the conditions reported in 1982161 for deprotection of the Mtr group from Trp, Lys and the 
imidazole group of His (MSA/ EDT/thioanisole 85.5/4.5/10 v/v/v), but also in this case 
decomposition and traces of the presence of the ligand lacking in the Indolyl group was detected by 
mass spectrometry (results not shown). A possible explanation for this reaction outcome is that the 
methyl indolyl moiety, linked to the nitrogen of the DKP, is more susceptible to electrophilic 
substitution. Anyhow the problem is not related to the Mtr-deprotection from the Indolyl moiety, 
but it is related to the intrinsic structure of our ligand. To overcome this problem, it is clear that a 
change in the synthetic pathway and, more specifically, in the protecting group scheme would be 
necessary. However, this would introduce an even higher degree of complexity; to avoid this, we 
considered a different strategy to introduce the required cadherin binding epitope. This will be 
illustrated in the next paragraph. 
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2.2.3 Synthesis of cyclic ligands 
In order to synthesize valuable ligands for cadherin homophylic interactions, we continued our 
investigations in this field. We decided to switch our attention towards cyclic ligands based on the 
DKP3 scaffold and containing amino acids bearing the correct functionalities to interact with the 
protein. Docking studies with human E-cadherin and molecular dynamics simulations were 
therefore set up and the c(DKP3-Gly-Arg-Trp) (61, Figure 39) resulted to be a very interesting 
ligand. 
Cyclic peptides show a better biological profile compared to their linear homologues, due to their 
conformational rigidity.  In addition, they show resistance to hydrolysis by peptidases due to the 
lack of both amino and carboxyl ends and crossing the cell membrane is enhanced with respect to 
the linear peptides. The role of cyclic peptides in clinic is important. Tyrocidine A and Gramicidine 
S in Figure 40 (which showed antibacterial activity), are only examples to confirm this.162 
 
Figure 40 Structure of tyrocidine A (left) and Gramicidine S (right). 
 
The synthesis of the c(Gly-DKP3-Trp-Arg) was planned in solution. First the scaffold COOH-
DKP3-NHBoc 82 was synthesized as previously reported by our group.52 Scheme 12 shows the 
synthetic pathway for the DKP3 scaffold.  
A serine ligation strategy was selected.81 Starting from either (S)-Ser and (R)-Asp, (S)-N-
benzylserine methyl ester 77 and (R)-N-(tert-butoxycarbonyl)aspartic acid β-allyl ester 20 were 
easily prepared according to literature procedure.158,159 Direct coupling between 20 and 77 was 
chosen (in order to avoid the introduction of further protecting groups) and the generation of the 
isopeptide 78 was achieved in high yield (67%), instead of the expected dipeptide 78*.81 After boc-
deprotection of 78 and cyclization to obtain 79, the introduction of the azide group was carried out 
through a Mitsunobu-type reaction (75%). The azido derivative 80 was converted into the NHBoc-
compound 81 through one-pot Staudinger reduction-Boc protection (68%). De-allylation (via a 
Pd(0) catalyzed Tsuji-Trost reaction) followed to afford the final product 82 in almost quantitative 
yield. 
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Scheme 12 Synthesis of the scaffold DKP3 (82). Reagents and conditions: a) EDC·HCl, DMAP, DCM, r.t., o.n., 67%; b) 
TFA/DCM 1:2 (v/v), 0°C to r.t.; c) DIPEA, iPrOH, r.t., o.n., 80%; d) HN3, DIAD, PPh3, DCM/toluene 4:6 (v/v), 6h, -
20°C, 75%; e) Me3P, BocON, THF, -20°C to r.t., 68%; f) pyrrolidine, PPh3, [Pd(PPh3)4], DCM, 0°C to r.t., quant. 
 
The mechanism of the isopeptide formation was deeply studied by means of NMR in our research 
group (Scheme 13).81 NMR spectra confirmed the mechanism via O,N-acyl transfer.163 Selective 
O-acylation of the unprotected β-hydroxyl group of N-benzylserine methyl ester is preferred over 
the formation of the tertiary amide. In addition the resulting ester bond is stable in solution to O,N-
acyl transfer which occurs spontaneously upon Boc- deprotection with simultaneous formation of 
the diketopiperazine ring. 
 
 
 
Scheme 13 DKP formation mechanism from the isopeptide 
 
The conversion of the hydroxyl group to the azide group (compound 79 into 80) was achieved 
through the Mitsunobu reaction (Scheme 14). The reaction is critical since the activated hydroxyl 
functionality could undergo β-elimination before reacting with the nucleophile hydrazoic acid. The 
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reaction was monitored and the temperature was kept around -20°C in order to minimize the 
formation of the β-elimination product (83). 
 
Scheme 14 Mitsunobu-type reaction mechanism on the DKP scaffold 
 
The conversion of 80 into 81, involved a one-pot Staudinger reduction-Boc protection. The azide 
reacts with the phosphine to generate phosphazide intermediate which then loses N2 forming an 
iminophosphorane. In this one-pot Staudinger-Boc protection, the iminophosphorane reacts directly 
with 2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON) affording the desired Boc-
protected amine in very good yield. Notably, in a classical Staudinger reaction, the hydrolysis of 
this last intermediate leads to the amine and the very stable phosphine oxide. The mechanism is 
reported in Scheme 15. 
 
 
Scheme 15 One-pot Staudinger-Boc protection reaction on the azide 
 
Deallylation on 81 was performed in the presence of a catalytic amount of Palladium 
tetrakis(triphenylphosphine) ([Pd(PPh3)4]), and pyrrolidine (which is necessary as allyl scavenger) 
as nucleophile (catalytic cycle in Scheme 16). Such methodology is particularly interesting for 
peptide synthesis because of the compatible deprotection conditions in the presence of labile tBu 
and Boc groups.164 The final amino acid derivative (82) was obtained in good yields (80-90%). 
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Scheme 16 Deallylation mechanism 
 
Once we synthesized the DKP3 scaffold 82, we continued the synthesis of the cyclic ligand in 
solution. The synthetic pathway is depicted in Scheme 17. Compound 84 was synthesized in good 
yield (80%), starting from 82 and Gly-OBn HCl, using HATU and HOAt as coupling agents and 
DIPEA as a base. After Boc deprotection, Fmoc-Trp(Boc)-OH was coupled using the same 
coupling conditions as the previous step, obtaining compound 85. The tryptophan was chosen 
Fmoc- and Boc- protected in order to fulfill the orthogonality with the OBn-protecting group on the 
Glycine. Fmoc- deprotection to set the tryptophan’s amino group free was achieved in quantitative 
yield, treating the peptide with piperidine in DMF. Coupling with Cbz-Arg(Mtr)-OH was done 
directly on the crude Fmoc- deprotected compound and 86 was obtained in good yield (70%). Once 
the linear peptidomimetics Cbz-Arg(Mtr)-Trp(Boc)-DKP3-Gly-OBn (86) was obtained, it was 
deprotected from the Cbz and Bn groups through hydrogenolysis. The linear deprotected derivative 
(87) was subjected to macrolactamization. The protected cyclic peptide 88 was obtained in a fairly 
good yield (60%). A final side-chain deprotection afforded the desired compound (61) which was 
purified by preparative HPLC (30% yield). 
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Scheme 17 Synthetic pathway for c(Gly-DKP3-Trp-Arg) (61). Reagents and conditions: a) Gly-OBn HCl, HATU, HOAt, 
DIPEA, dry DMF, 0°C to r.t., under N2, 93%; b) 1) TFA/DCM 1:2 (v/v), 0°C then r.t. 2) Fmoc-Trp(Boc)-OH, HATU, HOAt, DIPEA, 
dry DMF, 0°C to r.t., under N2, 60%; c) 1) piperidine in dry DMF, 2h, under N2; 2) Cbz-Arg(Mtr)-OH, HATU, HOAt, DIPEA, dry 
DMF, 0°C to r.t., under N2, 72%; d) H2, Pd/C, THF/water 1:1, r.t., o.n., quant.; e) HATU, HOAt, DIPEA, DMF, 0°C to r.t., under N2, 
60%;
 
f) TFA/Thioanisole/EDT/anisole 90/5/3/2, 2h, 30%. 
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2.3 Conclusions and outlooks 
A second generation of linear peptidomimetic inhibitors of cadherin homophilic interactions (76) 
was developed, bearing the newly synthesized DKP3-indolyl scaffolds 70. Unfortunately, problems 
during the final deprotections of 76 were faced, so the final linear peptide fully deprotected (59) 
was not detected. A new synthetic pathway, likely involving the use of a different protecting group 
strategy, needs to be developed although this would involve a cumbersome work to define the 
complete orthogonality among the different groups. 
In alternative, a new cyclic peptidomimetic ligand 61 was synthesized. In this case the indolyl 
moiety was inserted as amino acid tryptophan in the ligand together with Arginine, Glycine and the 
DKP3 scaffold. Compound 61 will be tested for its ability to inhibit calcium dependent cadherin 
binding using N- or E-cadh-expressing cell lines. 
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PART II 
 
1. Design of cyclic CPP-DKP scaffolds for drug delivery 
 
1.1 Cyclic peptides as therapeutic agents 
 
Chemists have been attracted by cyclic molecules for a long time, especially after the discovery of 
Gramicidin S (Figure 41) in 1944 by Gause and Brazhnikova. Gramicidin S was used to treat 
septic gunshot wounds during the Second World War, as 
it showed antiseptics activity.165 Since then, cyclic 
peptides have gained significant therapeutic potential and 
many have been used as therapeutic agents (e.g. 
octreotide, calcitonin, cyclosporine A, etc.)166 also in 
consideration of their increased resistance to proteases 
with respect to linear 
p
e
ptides. Cyclosporin A (Figure 42) is an orally bioavailable 
peptide drug due to its high membrane permeability; it was 
approved in 1983 as an immunosuppressive therapeutic drug in 
patients undergoing transplants.167 Romidepsin (Figure 43) is a 
potent antitumor drug which induces apoptosis in malignant 
cells.168 
Cyclization of certain sequences of membrane-active peptides 
enhances their antimicrobial activity. The restriction of the 
available conformations is 
crucial for ensuring a better 
activity. In fact, cyclic peptides can adopt an amphipathic 
arrangement and, in this way, they are able to perturb the 
membrane by forming pores. Such conformations are more 
seldom met in linear peptides, in which entropy reduces the 
formation of structures with amphipathic-like character.169  
 
 
  
Figure 43 Romidepsin 
Figure 3.1 Gramicidin S 
Figure 42 Cyclosporin A 
Figure 41 Gramicidin S 
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1.1.1 Peptide’s macrocyclization 
Cyclic peptides, especially larger ones, are notoriously difficult to synthesize. The ground-state E 
geometry is important; because of this geometry, small and medium-sized ring are unable to 
assume the ring like conformation which is essential for obtaining cyclization. Of course this is not 
the case of larger cycle, which in turn have the problem to avoid intermolecular reactivity.  
Peptide cyclization can be achieved in different ways: head-to-tail (N-terminus to C-terminus), 
head-to-side chain, side chain-to-tail or side-chain-to-side-chain as represented schematically in 
Figure 44.170 
 
 
 
 
Macrocyclization gives the best yields if a high dilution strategy is used; for this reason, solid-
supported macrocyclizations can be very effective.171 Several efforts have been done for directing 
macrocyclization over the past years: conformational pre-organization172, formation of internal 
hydrogen bonds or β-sheet structures173, introduction of pseudo-proline174, metal-ion assisted 
cyclizations175, etc. are only some ways used to improve macrocyclization. 
 
 
1.2 Cyclic cell penetrating peptides 
 
As discussed in Part I, cell penetrating peptides are considered promising devices for medical 
development. Peptide cyclization was demonstrated to be an effective strategy for enhancing 
cellular uptake rates and promoting endosomal escape thus enhancing cytoplasmic distribtion.176–179 
In 2011 Lättig-Tünnemann et al. demonstrated that the transduction entrance efficiency (which 
corresponds to a non-endocytic mode of entry cells) of arginine-rich peptides is enhanced when 
guanidinium groups are forced into maximally distant positions simply by peptide cyclization. The 
higher structural rigidity of the arginine-rich peptides leads to higher uptake rate with respect to the 
flexible linear counterpart.177 
In the majority of the literature’s cases, peptide cyclization is achieved via the chemoselective 
copper-catalyzed azide-alkyne cycloaddition (CuAAC).180,181 In particular, triazole-bridged cyclic 
Figure 44 Schematic representation of different ways for peptides cyclization. Adapted from ref 174 
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peptides were synthesized and characterized, in the laboratories of Professor Neundorf’s group 
(University of Cologne) where I spent a six-month research period.114,182  
For example, the synthesis and biological evaluation of a CPP based on human calcitonin (hCT) 
was reported by Neundorf’s group. Side-chain cyclization was achieved via CuAAC reaction 
(Figure 45).  
 
 
N
o cytotoxic effects and efficient intracellular uptake were determined for the peptide in Figure 45. 
Moreover, preliminary studies using this novel peptide as drug transporter for daunorubicin were 
performed. 
On the other hand, a fragment of the cell penetrating peptide sC18 (106GLRKRLRKFRNK117 
namely sC18*) was cyclized via CuAAC reaction, with different ring size (obtaining cyclic 
molecules 89, 90, 91, Figure 46).114 Substitution of glycine and lysine by propargylglycine and ε-
azidolysine respectively, allowed for selective side chain cyclization via “click chemistry”. The 
three cyclic peptides differ essentially for the number of arginine residues which are incorporated 
into the cyclic moiety, with the aim of studying how the amount and position of guanidinium 
groups affect the peptide membrane activity. Their proteolytic stability was tested and they showed 
to be much more stable than the linear peptides. Furthermore, the cyclic peptide did not show any 
cytotoxicity when incubated with different human cell lines such as human breast adenocarcinoma 
cells (MCF-7), colon adenocarcinoma cells (HCT-15), cervical carcinoma cells (HeLa), and 
embryonic kidney cells (HEK-293). Interaction studies using artificial membrane systems were 
conducted and all the cyclic peptides readily translocated through the membrane; among the three 
cyclic peptides, cyclic 91 (Figure 46) showed the highest membrane translocation activity.114 
 
 
 
 
 
 
 
 
 
89 90 91 
Figure 46 sC18 cyclic peptides containing one (89), three (90) or four (91) arginine residues in the cyclic moiety. 
Figure 45 Cyclic hCT(9-32). Adapted from reference 186 
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1.3 Aim of the project  
 
Encouraged by these results, in collaboration with Lucia Feni (PhD student in Professor Neundorf’s 
group, Institute of Biochemistry, University of Cologne), we planned to replace the triazole bridge 
of compound 91 with a more spatially oriented and rigid scaffold such as the bifunctional 
diketopiperazines (DKP) showed in the previous chapter, thus developing new cyclic sC18* 
peptides which correspond to cyclic peptide 91. The cis- (DKP1) and trans- (DKP3) 
diketopiperazine rigid scaffolds were used for the synthesis of compound 92 and 93, (Figure 47) 
respectively. 
 
 
 
 
  
Figure 47 sC18-cyclic peptides with the cis-DKP scaffold (structure 92) and the trans-DKP scaffold (structure 93). 
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1.3.1 Synthesis of c(sC18*-DKP) 
 
First of all, scaffolds DKP1 and DKP3 were synthesized as reported in Scheme 18. Compounds 80 
and 97 were synthesized as previously reported in Part I (Paragraph 2.2.3, Scheme 12), starting 
from L-Ser and L-Asp for 97 (Scheme 18) and starting from L-Ser and D-Asp for compound 80 
(Scheme 18). We decided to avoid the use of a protecting group on the DKP scaffold keeping the 
azido group on the DKP scaffold and to reducing it to amino group directly on resin.  
Compounds 98 and 99, were synthesized treating compounds 97 and 80 with a catalytic amount of 
Pd[P(Ph3)]4 in presence of N-methylaniline to remove the allyl ester and to obtain the desired azido 
acids. 
 
 
 
 
Scheme 18 Synthesis of the DKP1 and DKP3 scaffolds. Reagents and conditions: a) EDC·HCl, DMAP, DCM, 67%; b) 
TFA/DCM 1:2 (v/v), 0°C to r.t.; c) DIPEA, iPrOH, o.n., r.t., 80%; d) HN3, DIAD, PPh3, DCM/toluene 1:2 (v/v), 6h, 75% 
(58% for 96); e) Pd[P(Ph3)]4, N-methylaniline, dry DCM, under N2, 60%. 
 
With the azido acids 98 and 99 in our hands, the synthesis of the sC18-DKP linear peptides was 
performed on solid phase through automated SPPS. 
Different strategies were adopted for the synthesis of the cyclic compounds, as shown in the 
retrosynthetic Scheme 19. 
The two synthetic pathways differ essentially for the site of cyclization. In pathway A the amino 
group of the DKP scaffold is involved in the formation of the peptide bond with the C-terminal 
carboxyl group, while in pathway B cyclization was achieved through the formation of peptide 
bond between two amino acids in the sC18* sequence (as showed in Scheme 19). In fact, we 
planned to exploit the tendency of the cis-DKP1 scaffold to keep the two branched ends in the 
same direction, like forming a β-sheet,13 trying to achieve a higher level of preorganization in the 
final structure. 
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Synthetic pathway A (for both cycle 92 and 93) is reported in Scheme 20. sC18* peptide was 
synthesized as C-terminal acid on a Fmoc-Lys(Boc)-OH, preloaded 2-chlorotrytil chloride resin, by 
automated multiple solid-phase peptide synthesis (Fmoc strategy). Compounds 98 and 99, DKP1 
and DKP3 respectively, were coupled manually to the peptide using Oxyma and DIC as coupling 
agents (101, Scheme 20). Reduction of the azido group on the DKP scaffolds (102) was achieved 
using a 2M solution of DL-dithiothreitol (DTT) in DCM and in presence of DIPEA in almost 
quantitative yields. Full cleavage of the peptide from the resin was done using weak acidic 
conditions (acetic acid) in order to obtain the peptide fully protected at the amino acid side chains 
(103). In this way only the C-term and the N-term are free to react, forming a peptide bond. The 
cyclization step was done using PyBOP, HOBt as coupling agents and DIPEA in DMF. Final 
deprotection was achieved with TFA in the presence of scavengers such as phenol, water, 
thioanisole, EDT. The peptides were then purified on HPLC, yielding the cyclic compounds 92 and 
93. 
The cyclization step was most challenging; overall yields were quite low for both cyclic peptides 
(the best result was 16% yield). However, considering the length of the peptide, we considered 
such yields acceptable. In some cases the presence of epimers was detected by LC-MS (data not 
shown). 
 
Scheme 20 Synthesis of the two sC18-cyclic peptides with the cis-DKP scaffold (92) and the trans-DKP scaffold (93). 
Reagents and conditions: a) Oxyma, DIC, o.n.; b) DTT (2M), DIPEA (1M), DCM, 2h; c) acetic acid/ TFE/ DCM 1:1:8; d) 
[0.65mM] peptide concentration, PyBOP (5eq), HOBt (5eq), DIPEA (6eq), dry DMF, 24h, r.t.; e) full deprotection with 
TFA/phenol/water/thioanisole/EDT 82,5:5:5:5:2,5. 
Scheme 19 Retrosynthetic pathways for the synthesis of the cyclic [sC18*-DKP] compounds 92 or 93  
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Trying to obtain better yields, we decided to synthesize cyclic peptide 92 (containing the cis-DKP1 
scaffold) as proposed in pathway B (Scheme 21). The sC18* sequence was synthesized again on 
solid phase but anchoring the peptide to the resin through Lys113 (instead of the N-terminal Lys117 
as in pathway A). After coupling the DKP1 scaffold, the peptide was elongated by manual coupling 
of the remaining amino acids, obtaining the linear peptide 108. The latter was cyclized using the 
same condition of pathway A. Yields around 7 % were obtained, probably due to the formation of 
truncated sequences during the elongation step after DKP coupling.  
 
 
 
 
 
  
Scheme 21 Synthetic strategy relative to pathway B. Reagents and conditions: a) HATU, DIPEA, 2h; b) DTT (2M), 
DIPEA (1M), DCM, 2h; c) elongation with Lys, Asn, Arg and Phe; d) acetic acid/ TFE/ DCM 1:1:8; e) [0.65mM] peptide 
concentration, PyBOP (5eq), HOBt (5eq), DIPEA (6eq), dry DMF, 24h, r.t.; f) full deprotection with 
TFA/phenol/water/thioanisole/EDT 82,5:5:5:5:2,5. 
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1.3.2 Synthesis of c-sC18*(reversed sequence)-DKP 
 
In addition, a linear sC18* with C-term and N-term exchanged (sequence: 
117KNRFKRLRKRLG106) was also synthesized and its cyclized version with cis-DKP1 (109) 
was developed. 
 
 
 
 
 
 
 
 
 
 
 
The synthesis of the cyclic version of a reversed sC18*-DKP1 peptide was done as reported in 
Scheme 22. In this way, the cyclization occurs on the glycine residue which can not undergo 
epimerization. 
 
 
 
 
 
 
 
 
 
 
 
The peptide was synthesized on a H-Gly-OH preloaded 2-chlorotrytil chloride resin by 
automated multiple solid-phase peptide synthesis (Fmoc strategy) using a robot system. The 
synthetic strategy is the same as in path a (Scheme 20) and in this case yields were around 3-6 %. 
  
Figure 48 c(rev-sC18*-DKP1) compound 109 
Scheme 22 Synthesis of c(rev-sC18*-DKP1) 109. Reagents and conditions: a) Oxyma, DIC, o.n.; b) DTT (2M), 
DIPEA (1M), DCM, 2h; c) acetic acid/ TFE/ DCM 1:1:8; d) [0.65mM] peptide concentration, PyBOP (5eq), HOBt 
(5eq), DIPEA (6eq), dry DMF, 24h, rt; e) full deprotection with TFA/phenol/water/thioanisole/EDT 82,5:5:5:5:2,5. 
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1.3.3 Synthesis of linear sC18*-DKP 
 
Linear peptides corresponding to the cyclic 91 and 92 were also synthesized in order to study their 
behaviour and compare it with the cyclic versions. Their synthesis is reported in Scheme 23. 
 
 
 
 
Linear peptides sC18*-DKP 102a and 102b were treated with a mixture of TFA:TIS:water in order 
to obtain both cleavage from the resin and deprotection of all the amino acids’ side chains. Peptides 
114a and 114b were purified on preparative HPLC, obtaining final peptides (60% yield for 114a 
and 48% for 114b) with purities >95%. 
Scheme 23 Synthetic strategy for linear peptides (114a and 114b). Reagents and conditions: a) Oxyma, DIC, o.n.; b) 
DTT (2M), DIPEA (1M), DCM, 2h; c) full cleavage with TFA:TIS:water 9.5:2.5:2.5 for 3h at rt (60% for 114a and 
48% for 114b). 
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1.4 Structural investigations on cyclic (92 and 93) and linear (114a, b) 
peptides 
 
- Circular Dichroism studies 
 
Cyclic peptides 92 and 93 were studied with CD spectroscopy to evaluate their secondary structure. 
The CD spectrum is generated from the sum of contributes of each amide moiety present in the 
peptide; in fact, the chromophores of the amides, aligned in different ways, result in the fact that 
each structural element has characteristic CD spectra (Figure 49). For example, α-helical peptides 
have negative bands at 222 nm and 208 nm and a positive band at 193 nm. Peptides with 
antiparallel β-sheets have negative bands at 218 nm and positive bands at 195 nm, while disordered 
proteins have very low ellipticity above 210 nm and negative bands near 195 nm.183 
 
 
 
In Figure 50, CD spectra of the cyclic peptides 92 and 93 in phosphate buffer and in presence of 
trifluoroethanol, are reported. Trifluoroethanol (TFE) is a cosolvent which has been widely used in 
the field of structural biology as membrane mimetic agent.184 Compounds 92 (cDKP1) and 93 
(cDKP3) in PBS buffer seem to adopt disordered structures, whereas in the presence of TFE, the 
peptides seem to be more structured with two minima around 203 nm and 222 for peptide 92 and 
two less intense minima around 210 and 222 for peptide 93; anyway their behavior does not fit 
with any canonical secondary structure. 
CD spectra of the linear versions, 114a and 114b, are also reported in Figure 50; the two linear 
versions assume disordered structures in phosphate buffer, while they seem to reorganize in α-
helical structures in presence of TFE as usual for sC18 linear peptides. As a consequence, the DKP 
scaffolds did not perturb the properties of linear sC18 in phosphate buffer. 
Figure 49 CD spectra of representative secondary structures. In particular, 1 (black) α-helical, 2 (red) 
antiparallel β-sheet and 3 (cyan) disordered conformations. Adapted from ref 187 
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Figure 50 CD spectra of cyclic 92 (blue line) and 93 (red line) and linear 114a (dashed blue line) and 114b 
(dashed red line) in PBS buffer and in presence of 50% TFE. 
72 
 
 
Figure 51: Overlapping of the 20 energy-favored structures of peptide 114a (left) and 114b (right) in the presence 
of SDS micelles. The backbones of these linear peptides show an α-helical structure.  
 
- NMR studies 
In collaboration with Dr. Díaz (Organic Chemistry, University Cologne), the three dimensional 
structures of both linear and cyclic derivatives of DKP1-sC18 peptide were investigated by NMR 
spectroscopy.  
The conformational preferences of the peptides in solution and also in membrane mimetic medium 
(i.e. SDS micelles, SDS= sodium dodecyl sulfate) were studied in order to explore details about the 
translocation’s mechanism of CPPs inside the cells, using a simple model system.  
The linear peptides 114a and 114b were analyzed in solution. After assignment of the NMR signals 
and using the array of internuclear distances derived from the NOESY spectra, the conclusion was 
that both peptides exhibit a random coil structure in solution, as not identifiable secondary structure 
was found, no matter the temperature we used to acquire the spectra (i.e. 283 K or 298 K).  
On the other hand, both peptides were found to assume α-helix structures in presence of SDS 
micelles (Figure 51). This result is not surprising since it is known that the structure of the native 
CAP18 peptide switches from random coil to helix upon addition of TFE. The presence of DKP1 in 
the sequence does not seem to play a role since any special interaction between DKP1 and any 
other residue of the peptide sequence (i.e. participation in hydrogen bonds to stabilize the helix) 
was detected. The position of the residue (first residue, N-terminus) seems to preclude such 
possibility and it is not involved in helix stabilization. 
 
 
 
 
 
 
 
For what concerns the cyclic peptide DKP1-sC18 92, NMR spectra at 298 K were acquired and an 
ensemble of structures using experimental NOE restraints (internuclear distances) were calculated, 
obtaining the ten lowest energy structures for peptide 92 (Figure 52). 
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Cyclic peptide 92 does not show signs of secondary structure in solution at 298 K. On the other 
hand, spectra acquired at 283 K, in particular NOESY spectra, showed a relatively large number of 
NH-NH cross peaks, suggesting that temperature influences the equilibrium between different 
conformations of the peptide and supporting the existence of structural families/clusters. Anyway, 
the temperature coefficients do not support this assumption and they seem to indicate absolute 
absence of hydrogen bonds. Further investigations are ongoing (molecular dynamics) in order to 
explore the possible compatibility with the experimental data and whether they could be explained, 
with the experimental NMR restraints deduced from the spectra (i.e. NOE cross peaks and the 
corresponding internuclear distances). 
The NMR analysis of both cyclic peptides 92 and 93 in presence of SDS micelles are still ongoing. 
  
Figure 52: Ensemble of the 10 lowest energy structures of cyclic peptide 92. For the sake of clarity only 
backbone traces are shown (black) and the linker DKP1 (red) at 298K. 
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1.5 Conclusions and outlooks 
New cyclic sC18* peptides, bearing cis- (DKP1) and trans- (DKP3) diketopiperazine rigid 
scaffolds, were synthesized (compound 92 and 93, Figure 47). Different retrosynthetic approaches 
were used for their synthesis trying to enhance the cyclization yields; unfortunately, no big 
differences were found in yields of this last step. Linear counterparts (114a and 114b) of the cyclic 
compounds were also synthesized in order to study their characteristics and supposed different 
behavior towards membrane mimetic media.  
Structural investigation on cyclic compounds 92 and 93 was done through circular dichroism 
studies and in addition, the three dimensional structures of both linear and cyclic derivatives of 
DKP1-sC18 peptide was investigated by NMR spectroscopy in collaboration with the University of 
Cologne.  
Structures of cyclic compounds, both in absence and in presence of TFE, seemed not to fit with any 
canonical secondary structure (CD spectra). Linear peptides 114a and 114b were analyzed in 
solution, by mean of NMR, and both peptides exhibit a random coil structure in solution. On the 
other hand, both linear peptides were found to assume α-helix structures in presence of SDS 
micelles.  
Further investigations in this field are ongoing for the cyclic compounds 92 and 93. We are 
currently planning to develop labeled and drug-conjugate with cyclic compounds in order to study 
their biological activity and the possibility to use them as drug delivery systems. 
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Experimental part 
General Remarks and Procedures 
Materials and methods 
 
All manipulations requiring anhydrous conditions were carried out in flame dried glassware, with 
magnetic stirring and under a nitrogen atmosphere. All commercially available reagents were used 
as received. Anhydrous solvents were purchased from commercial sources and withdrawn from the 
container by syringe, under a slight positive pressure of nitrogen. The reactions were monitored by 
TLC using silica gel 60 F254 pre-coated glass plates (0.25 mm thickness). Visualization was 
accomplished by irradiation with a UV lamp and/or stining with a potassium permanganate alkaline 
solution, ninhydrin or ceric ammonium molibdate solution. Flash column chromatography was 
performed according to the method of Still and co-workers185 using Chromagel 60 ACC (40-63 
μm) silica gel. Proton NMR spectra were recorded on a spectrometer operating at 400.16 MHz. 
Proton chemical shift are reported in ppm (δ) with the solvent reference relative to TMS employed 
as the internal standard. The following abbreviations are used to describe spin multiplicity s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad signal, dd = doublet of 
doublet, ddd = doublet of doublet of doublet, ddt = doublet of doublet of triplet. Carbon NMR 
spectra were recordered on a spectrometer operating at 100.63 MHz, with complete proton 
decoupling. Carbon chemical shift are reported in ppm (. δ) relative to the TMS with the respective 
solvent resonance as the internal standard. ESI-MS spectra were recordered on the ion trap 
spectrometer Finnigan LCQ Advantage. 
 
RP-HPLC purification and analysis (University of Milan) 
The HPLC purifications were performed using a Dionex Ultimate 3000 instrument equipped with a 
Dionex RS Variable Wavelenght Detector (column: Atlantis® Prep T3 OBDTM 5 μm 19 × 100 
mm). The crude reaction mixture was dissolved in water and the solution was filtered 
(polypropylene, 0.45 μm, 13 mm ɵ, PK/100) and injected in the HPLC, affording purified products. 
Purity analysis for each compound was carried out on a Dionex Ultimate 3000 instrument equipped 
with a Dionex RS Variable Wavelenght Detector (column: Atlantis® Prep T3 OBDTM 5 μm 19 × 
100 mm). 1 mg of purified product was dissolved in 1 mL of H2O and was injected using the same 
gradient used in the purification step. The analysis of the integrals and the relative percentage of 
purity was performed with the software Cromeleon 6.80 SR11 Build 3161. 
 
RP-HPLC purification and analysis (University of Cologne) 
 
Purity determination by analytical HPLC and qualitative analysis by HPLC-ESI-MS  
In order to determine peptides identity and final purity, the samples were analysed by HPLC-ESI-
MS (LC-MS) for qualitative analysis and by RP-HPLC for purity determination. The flowrate used 
was 0.6 mL/min, detection took place at 220 nm. Samples were diluted 1:1 in H2O/ACN/additive 
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(90:10:0.1, v/v/v). The chromatography was performed on a linear gradient ranging from 10% - 
60% B in A (A: 0.1% additive in H2O, B: 0.1% additive in ACN) over 15 min, or 10% - 50% B in 
A over 25 min. Purity of a sample was determined by calculating the ratio of the product peak area 
to the total peptide peak area in the UV-chromatogram. For qualitative analysis, FA was used as an 
additive. For purity determination, TFA was used instead, as it results in a more constant 
background in the UV-chromatogram. 
 
Peptide purification by preparative RP-HPLC: the crude peptide mixture was dissolved in 
H2O/ACN/TFA (90:10:0.1, v/v/v) and centrifuged at 14,000 X g for 5 min. The supernatant was 
transferred into a glass reservoir for sample injection. The chromatography was performed on a 
linear gradient of B in A (A: 0.1% TFA in H2O, B: 0.08% TFA in ACN) which varied depending 
on the composition of the crude peptide mixture. The flowrate used was 6 mL/min on the full-
preparative column for samples containing more than 6 mg of peptide, or 1.5 mL/min on the semi-
preparative column for samples containing 6 mg of peptide or less. Peptides were detected at 220 
nm and 250 nm and peptide containing fractions were collected accordingly. Afterwards, ACN was 
removed from the fractions by an evaporation and concentration system and then used in a 1:1 
dilution with H2O/ACN/FA (90:10:0.1, v/v/v) or H2O/ACN/TFA (90:10:0.1, v/v/v) for qualitative 
analysis or purity determination by HPLC-ESI-MS, respectively. Fractions containing pure samples 
of the desired peptide were combined and freeze-dried.  
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General procedures for solution phase synthesis 
 
GP1. GENERAL PROCEDURE 1 FOR Boc DEPROTECTION REACTIONS: 
To a solution of the N-Boc-protected amino acid or peptide in CH2Cl2 (0.13 M) was added half a 
volume of TFA. The reaction mixture was stirred for 2h at r.t. and then concentrated at reduced 
pressure. The excess of TFA was azeotropically removed from the residue with toluene. Diethyl 
ether was added and the resulting suspension was evaporated under reduced pressure to afford the 
corresponding TFA salt. 
 
GP2. GENERAL PROCEDURE 2 FOR COUPLING REACTIONS: 
To a solution of the N-protected amino acid in DMF, under nitrogen atmosphere and at 0°C, HATU 
(1.3 eq), HOAt (1.3 eq) and DIPEA (4 eq) were added successively. After 30 min, a solution of the 
N-deprotected TFA salt of the peptide in DMF was added and the reaction mixture was stirred at 
0°C for 1h and at r.t. overnight. The mixture was afterwards diluted with EtOAc and consecutively 
washed with 1M KHSO4 (2x), acqueous NaHCO3 (2x) and brine (2x), and dried over Na2SO4. 
Volatiles were evaporated under reduced pressure to afford the crude product. 
 
GP3. GENERAL PROCEDURE 3 FOR Cbz AND OBn HYDROGENOLYTIC 
CLEAVAGE: 
Protected compound (1 eq.) was dissolved in a mixture of THF/H2O (1:1) and Pd/C 10% (0.1 eq.) 
was added. The reaction mixtures were subjected to three vacuum/hydrogen cycles and then left 
stirring overnight at room temperature under 1 bar of hydrogen. The mixture was filtered through 
Celite, and the cake was washed thoroughly with THF/H2O (1:1). The filtrate was concentrated and 
dried to give the crude product as white solid (100%).  
 
GP4. GENERAL PROCEDURE 4 FOR MACROLACTAMIZATION: 
HATU (4 eq.), HOAt (4 eq.) and DIPEA (6 eq.) were added successively to a 1.4 Mm solution of 
deprotected linear compound (1 eq.) in DMF, under a nitrogen atmosphere and at 0°C. After 
stirring the reaction mixture at 0°C for 1 h, it was allowed to reach room temperature and stirred 
overnight. DMF was then removed under reduced pressure. The mixture was afterwards diluted 
with EtOAc and consecutively washed with 1M KHSO4 (2x), acqueous NaHCO3 (2x) and brine 
(2x) and dried over Na2SO4. Volatiles were evaporated under reduced pressure to afford the crude 
product. 
 
GP5. GENERAL PROCEDURE 5 FOR Mtr AND OtBu ESTER REMOVAL: 
Protected macrolactam was treated for 2h with TFA, in the presence of ion scavengers: thioanisole 
(5%), EDT (3%), anisole (2%). After TFA removal under reduced pressure, the residue was 
dissolved in a 1:1 mixture of diisopropyl ether/water. Phases were separated, and the aqueous layer 
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was washed several times with diisopropyl ether. The aqueous phase was concentrated under 
reduced pressure to give the crude product, which was purified by HPLC. 
 
GP6. GENERAL PROCEDURE FOR Fmoc DEPROTECTION REACTIONS: 
A 0.01 M solution of the N-Fmoc-protected compound (1 eq) in DMF was cooled to 0 °C under 
nitrogen atmosphere. Piperidine (5 eq) was added and the reaction was stirred at room temperature 
for 2 h. The mixture was diluted with EtOAc (20x volume of DMF) and washed twice with a 
saturated aqueous solution of NaHCO3. The organic phase was dried over Na2SO4 and concentrated 
at rotavapor. CH2Cl2 was added to the residue and evaporated to afford a yellow solid. The crude 
was left under vacuum for 2 h and then used as starting material for the subsequent step. 
 
Preparation of hydrazoic acid 
 
In a three-necked flask, NaN3 (3 g) was dissolved in H2O (3 mL). Once completely dissolved, 
toluene (20 mL) was added and the reaction mixture was cooled to 0°C under vigorous stirring. 
Concentrated H2SO4 (1.2 mL) was added extremely slowly, so that the solution temperature did not 
exceed 10°C. the reaction was stirred for 1 h at 0°C and then filtered on cotton wool. The residue 
was washed twice with toluene. The toluene solution was titrated by diluting 1 ml in distilled water 
(50 mL), and addition of NaOH (0.1 M) with phenolphthalein as indicator. 
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General procedures for SPPS 
All Nα-Fmoc protected amino acids were obtained from Iris Biotech (Marktredwitz, Germany), 
resins additionally from Merckmillipore (Darmstadt, Germany). Chemicals and one-use articles 
were produced by Alfa Aesar (Karlsruhe, Germany), Applichem (Darmstadt, Germany), Merck 
(Darmstadt, Germany), Roth (Karlsruhe, Germany), Sigma Aldrich (Taufkirchen, Germany), 
Sarstedt (Numbrecht, Germany) and Fischer Scientific (Pittsburgh, USA).  
Standard Nα-Fmoc protected amino acids were side-chain protected as follows: Trt (cysteine, 
histidine, asparagine, glutamine), OtBu (aspartate, glutamate), Boc (lysine) and Pbf (arginine). 
 
Automated solid phase peptide synthesis (SPPS)  
 
Full length peptides or parts of them were synthesized by a SPPS robot (Syro II peptide 
synthesizer, MultiSynTech , Witten, Germany).following the protocol given beneath. The required 
amino acid solutions and reagents were prepared manually. All amino acids were dissolved in 
DMF except for Phe, for which NMP was used.  
A Fmoc strategy was selected and the following resin were used: Fmoc-Rink amide resin (200 
mesh, loading: 0.48 mmol/g, Iris Biotech), H-L-Lys(Boc)-2CT (200-400 mesh, loading: 
0.74mmol/g, Iris Biotech), 2-Chlorotrityl chloride Resin (100-200 mesh, 1.6 mmol/g, Iris Biotech). 
The resin was swollen for 10 min in 800 μL DMF and the solvent was then removed. For the first 
Fmoc-group cleavage, 400 μL 40% piperidine in DMF were added to the resin (3 min reaction 
time), followed by removal of solvent and subsequent addition of 200 μL DMF and 200 μL 40% 
piperidine in DMF (10 min reaction time). The resin was then washed 4 times with each 600 μL of 
DMF. Subsequent Fmoc deprotections were performed by incubating the resin in 400 μL of 40% 
piperidine in DMF for 3 min, removal of the solvent, addition of 200 μL DMF and 200 μL 40% 
piperidine in DMF and letting the reaction take place for 10 min. Lastly, the resin was washed 4 
times each with 800 μL of DMF.  
Amino acids were coupled by adding 300 μL of the respective Nα-Fmoc-protected amino acid 
solution (corresponding to 8 eq.) to the resin, as well as 50 μL of 2.4 M Oxyma in DMF and 50 μL 
of 2.4 M DIC in DMF. The resin was incubated for 40 min with the reaction mixture, washed with 
800 μL of DMF and the coupling step was repeated once again in order to increase the reaction 
yield. The Fmoc-group of the newly attached amino acid was then cleaved, and the next amino 
acids coupled in the same manner by the robot until the desired sequence was synthesized. Finally, 
the resin was washed manually 5x with DMF, DCM, MeOH, and Et2O, respectively, and dried in a 
vacuum concentrator for 10 min. 
 
 
GP7 GENERAL PROCEDURE FOR MANUAL RESIN LOADING  
The first C-terminal amino acid was coupled manually to the resin. For this, the resin was first 
swollen in DMF for at least 15 min while shaking at r.t., followed by removal of the solution. 5 eq. 
of the Fmoc-protected amino acid to be coupled and 5 eq. of Oxyma were dissolved separately in 
200 μL DMF each and then mixed together. 5 eq. of DIC were added to the solution which was 
then loaded onto the resin. The reaction was performed o.n. (r.t., shaking). The next day, the resin 
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was washed 5x with DMF, DCM, MeOH, and Et2O, respectively, and dried in a vacuum 
concentrator for 10 min. If the loading was not sufficient, it was repeated.  
 
- Determination of resin loading 
The amount of loaded resin can be quantified by cleaving the Fmoc-group of the previously 
attached amino acid. The quantitative analysis is done by quantitative detection at 300 nm of the 
dibenzofulvene formed. For this, a defined amount of loaded resin was treated with 500 μL of 30% 
piperidine in DMF and shaken for 30 min at RT in order to cleave the Fmoc-group. After 
centrifugation, 250 μL of the supernatant were transferred into a new micro tube and mixed with 
1.5 mL of 30% piperidine in DMF. This solution was diluted 1:10 with 30% piperidine in DMF 
and its absorption at 300 nm measured in a quartz cuvette. The resin loading L300 in mmol/g was 
calculated as follows. 
 
L300 [mmol/g]: absorption at 300 nm; ε [M-1cm-1]: molar attenuation coefficient of dibenzofulvene 
(= 7800 M-1 cm-1); l [cm]: light path length; mresin [g]: mass of loaded resin; V[mL]: 1.75 mL. 
- Resin capping  
In order to prevent unreacted groups on the resin from coupling with amino acids during the 
ongoing peptide synthesis, these groups were blocked by acetylation. The resin was then swollen in 
1 mL DCM for 15 min and the solvent was removed. 400 μL DCM, 50 μL DIPEA and 50 μL acetic 
anhydride were added to the resin. After 15 min of shaking at RT, the solvent was removed; the 
resin was washed 5x with DCM, MeOH, and Et2O, respectively. Finally, the resin was dried for 10 
min in a vacuum concentrator. 
 
GP8. GENERAL PROCEDURE 8 FOR KAISER TEST: 
Kaiser test is used to detect free amino groups and thus to verify the completion of a coupling or 
deprotection reaction. A few resin beads were transferred into a 1.5 mL micro tube and treated with 
one drop of solution I (1.0 g Ninhydrin in 20 mL EtOH), solution II (80 g phenol in 20 mL EtOH), 
and solution III (0.4 mL aqueous KCN-solution (1 mM) in 20 mL pyridine), respectively. The 
mixture was incubated at 95 °C for 5 min in a thermomixer. The test was defined positive if the 
solution turned blue, indicating free amino groups. A yellow solution indicated a negative result 
with no free amino groups. A mixture without resin and a mixture with ethanolamine were used as 
negative and positive controls, respectively. 
 
GP9. GENERAL PROCEDURE 9 FOR MANUAL AMINO ACID COUPLING:  
In some cases, amino acids were coupled manually to ensure the maximum coupling yield. For this, 
the resin was first swollen in DMF for at least 15 min while shaking, followed by removal of the 
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solution. The Fmoc-group of the N-terminal amino acid was removed by treating the resin with 500 
μL 30% piperidine in DMF for 20 min (r.t., shaking). Afterwards, the resin was washed 5x with 
DMF and incubated again for 20 min in 500 μL 30% piperidine in DMF (r.t., shaking), followed by 
five washing steps with DMF. Next, 5 eq. of the Fmoc-protected amino acid to be coupled and 5 
eq. of Oxyma were dissolved separately in 200 μL DMF each and then mixed together. 5 eq. of 
DIC were added to the solution which was then loaded onto the resin. After 2 h, the resin was 
washed 5x with DMF and the coupling step was repeated once again. Finally, the resin was washed 
5x with DMF, DCM, MeOH, and Et2O and dried in a vacuum concentrator for 10 min. If the 
Kaiser test returned a positive result, the procedure was repeated once again under more vigorous 
conditions by replacing Oxyma and DIC with the stronger reagent HATU and DIPEA. 2 eq. of the 
Fmoc-protected amino acid to be coupled and 2 eq. of HATU were dissolved separately in 150 μL 
DMF each, mixed together and loaded onto the swollen resin. Then, 2 eq. of DIPEA were directly 
added to the reaction mixture and set aside for 2 h (r.t., shaking). The resin was then washed and 
dried. 
 
 
GP10. GENERAL PROCEDURE 10 FOR Fmoc DEPROTECTION  
After swelling the resin in DMF for 10 min, two deprotection steps were carried out treating the 
resin with 30% piperidine in DMF (2x20 min). The resin was then washed with DMF and the vial 
was empty. 
 
GP11. GENERAL PROCEDURE 11 FOR SAMPLE CLEAVAGE  
To verify the success of the coupling reactions and to analyse the resulting product, a sample 
cleavage was performed for every peptide and critical synthesis step.  
Few beeds of dry resin were transferred into a micro tube and the peptides cleaved off the resin by 
incubating the resin for 3 h (r.t., shaking) with 100 μL of a mixture of H2O/TIS/TFA (2.5:2.5:95, 
v/v/v). To precipitate the peptides, 1 mL ice-cold Et2O was added to the reaction and the mixture 
was stored for a minimum of 1 h or o/n at -20 °C. The peptides were washed five times by 
centrifugation at 10,000 x g and 4 °C for 5 min. After every centrifugation step, the supernatant 
was removed, and the precipitate resuspended in 1 mL ice-cold Et2O. After drying the precipitate in 
a vacuum concentrator for 15 min, it was dissolved in 100 μL H2O/tBuOH (2:1, v/v). After a final 
centrifugation step at 13,300 x g for 5 min, the supernatant was diluted 1:1 in H2O/ACN/FA 
(90:10:0.1, v/v/v) for qualitative analysis by HPLC-ESI-MS (LC-MS).  
 
GP12. GENERAL PROCEDURE 12 FOR FULL CLEAVAGE  
The dry resin was incubated for 3 h (r.t., shaking) with 1 mL of a mixture of H2O/TIS/TFA 
(2.5:2.5:95, v/v/v). To precipitate the peptides, the reaction mixture was added to 10 mL of ice-cold 
Et2O and stored at -20 °C for a minimum of 1 h or o/n. The peptides were then washed five times 
by centrifugation at 5000 x g and 4 °C for 5 min. After every centrifugation step, the supernatant 
was removed, and the precipitate resuspended in 10 mL ice-cold Et2O. After drying the precipitate 
in a vacuum concentrator for 15 min, it was dissolved in H2O/tBuOH (composition between 2:1 v/v 
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and 1:2 v/v, depending on the nature of the peptide). The peptide solution was diluted 1:1 in 
H2O/ACN/FA (90:10:0.1, v/v/v) for qualitative analysis by HPLC-ESI-MS (LC-MS). Finally, the 
peptides were freeze-dried. 
 
GP13. GENERAL PROCEDURE 13 FOR DKPs’ COUPLING 
The resin was swollen in DMF for at least 15 min while shaking, followed by removal of the 
solution. Next, 3 eq. of the 97 or 98 were weighted and 3 eq. of Oxyma were dissolved separately 
in 200 μL DMF each and then mixed together. 3 eq. of DIC were added to the solution which was 
then loaded onto the resin. After 2 h, the resin was washed 5x with DMF and the coupling step was 
repeated once again. Finally, the resin was washed 5x with DMF, DCM, MeOH, and Et2O and 
dried in a vacuum concentrator for 10 min. If the Kaiser test returned a positive result, the 
procedure was repeated once again under more vigorous conditions by replacing Oxyma and DIC 
with (the stronger reagent) HATU and DIPEA. 2 eq. of the Fmoc-protected amino acid to be 
coupled and 2 eq. of HATU were dissolved separately in 150 μL DMF each, mixed together and 
loaded onto the swollen resin. Then, 2 eq. of DIPEA were directly added to the reaction mixture 
and set aside for 2 h (r.t., shaking). The resin was then washed and dried. 
 
GP14. GENERAL PROCEDURE 14 FOR AZIDE REDUCTION ON RESIN 
The resin was then treated with DTT (2M) in 500µL of DCM. Then DIPEA (1M, 87µL) was 
added. The reaction was left shaking at room temperature for 2h. Then the solvent was sucked 
away and the resin was washed. washed 5x with DMF, DCM, MeOH, and Et2O and dried in a 
vacuum concentrator for 10 min. 
 
GP15. GENERAL PROCEDURE 15 FOR CLEAVAGE FROM THE RESIN 
The resin was treated with a solution of DCM:TFE:Acetic acid 8:1:1 for 2 h at r.t. to cleave the 
peptide from the resin without touching the protecting group on the side chains. The solution was 
put in a vial and the resin was washed two times more with the same solution DCM:TFE:Acetic 
acid 8:1:1 v/v/v. The solvent was evaporated under reduced pressure and the crude was subjected 
directly to the next step. 
 
GP16. GENERAL PROCEDURE 16 FOR FULL DEPROTECTION OF THE 
PEPTIDE 
The crude was treated with TFA/phenol/water/Thioanisole/EDT 82,5:5:5:5:2,5 v/v/v/v/v (1ml in 
tot). The reaction was kept under stirring at r.t. for 3h. Then the mixture was put in a vial 
containing 10 ml of cold Et2O in order to precipitate the peptide. The mixture was centrifuged and 
washed five times with cold Et2O. The crude was then dissolved in H2O:ACN 90:10 v/v + 0.1% 
TFA and purified on semipreparative RP-HPLC. 
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Synthesis of integrin ligand-based conjugates 
All the intermediates 19-28 (Scheme 1), 29-32 (Scheme 2) required for the synthesis of c[DKPf3-
RGD]-CH2NH2 15 were synthesized according to literature procedure and their analytical data 
were in agreement with those already published.51,52 
 
14-Azido-3,6,9,12-tetraoxatetradecanoic acid -NHS ester (33) 
 
 
 
100 μL (0.5 mmol, 1 eq.) of a 0.5 M solution of 14-azido-3,6,9,12-tetraoxatetradecanoic acid (0.5 
M in tert-butyl methyl ether) were diluted in 100 µL of dry DCM under argon and cooled to 0°C. 
EDC HCl (12,5 mg, 0.065 mmol, 1.3 eq.) and NHS (7.5 mg, 0.065 mmol, 1.3 eq.) were 
sequentially added to the solution and the reaction mixture was stirred overnight at r.t. The mixture 
was diluted in 10 mL of DCM and the organic phase was washed with water (3 × 3 mL), dried over 
MgSO4, filtrated and concentrated under reduced pressure to give the product as a transparent oil 
(18.2 mg, 97% yield). The crude product was used in next step without further modifications. 
Rf= 0.35 (DCM/MeOH 95:5); 1H NMR (400 MHz, CDCl3): δ 4.52 (s, 2H), 3.81–3.79 (m, 2H), 
3.68-3.65 (m, 12H), 3.39 (t, J = 5.0 Hz, 2H), 2.85 (s, 4H). 
 
 
C[DKPf3-RGD]-PEG-4-N3 (34) 
 
 
 
To a solution of compound 33 (8 mg, 21 µmol, 2 eq.) in 400 µL of ACN was added c[DKPf3-
RGD]-CH2NH2 (15) (9 mg, 11 µmol, 1 eq.) dissolved in 600 µL of PBS pH 7. The pH was adjusted 
to 7.4 with a solution of NaOH 0.2 M and the reaction was stirred overnight at room temperature. 
The mixture was filtered into a 3 mL vial, centrifuged and purified by preparative HPLC (gradient: 
from 90% (H2O + 0.1% TFA)/10% ACN) to 55% (H2O + 0.1 % TFA)/45% ACN in 16 mins, tR 
product = 8.8 min). The collected fraction was concentrated under reduced pressure and freeze-
dried from 1:1 water/ACN to afford the product as a white solid (5.3 mg, 40% yield).  
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1H NMR (400 MHz, D2O) δ 7.36 (dd, J = 15.6, 8.4 Hz, 4H), 5.13 (d, J = 15.5 Hz, 1H), 4.91 (m, 
1H), 4.63 – 4.59 (m, 1H), 4.50 (s, 3H), 4.32 – 4.17 (m, 3H), 4.15 (s, 2H), 4.12 (d, J = 4.1 Hz, 1H), 
3.99 (dd, J = 14.8, 4.6 Hz, 1H), 3.83 (d, J = 17.2 Hz, 1H), 3.77 (m, 2H), 3.75 – 3.70 (m, 3H), 3.69 
– 3.58 (m, 10H), 3.47 – 3.42 (m, 2H), 3.27 (m, 3H), 3.09 (dd, J = 15.1, 3.8 Hz, 1H), 2.69 (dd, J = 
15.1, 11.6 Hz, 1H), 2.05 – 2.01 (m, 1H), 1.88 – 1.83 (m, 1H), 1.74 – 1.63 (m, 2H); MS (ESI+): m/z 
calculated for [C37H56N13O13]+= 889.93 [M + H]+, found: 890.50. 
 
Dipeptide PropargylGly-Aoa (37) 
 
 
 
Dipeptide 37 was synthesized on solid phase using Fmoc-Rink amide resin (100-200 mesh, 
loading: 0.48mmol/g, 144µmol scale). Rink amide resin was deprotected from Fmoc group 
(GP10). Fmoc-PropargylGly-OH was manually coupled to the resin (GP7). After Fmoc- 
deprotection (GP10), (Boc)2Aoa-OH was coupled to the resin (GP9). The dipeptide was finally 
cleaved from the resin (GP12). The solid was solubilized in water:tBuOH 1:3 (v/v) and 
lyophilized. The crude was then purified on preparative RP-HPLC (10-60 ACN in 45 min). The 
desired product was obtained as a white foam (7.8 mg, 30%). MS (ESI+): m/z calculated for 
[C7H12N3O3]+= 185.18 [M + H]+, found: 186.09. 
 
 
PropargylGly-Aoa=Dau (38) 
 
 
 
The dipeptide propargylglycine-Aoa 37 (7.8 mg) was dissolved in 0.2M NH4OAc at a peptide 
concentration of 10 mg/mL. Then Dau was added in 30% excess (26 mg). The reaction mixture 
was stirred at r.t. for 12h. The reaction was check in LC-MS and the mixture was injected directly 
in HPLC and purified (20-70 ACN in 45 min). The final product 38 was obtained as a red solid 
(18,6 mg, 64%). MS (ESI+): m/z calculated for [C34H39N4O12]+= 695.69 [M + H]+, found: 
696.07.(SPK8) 
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c[DKPf3-RGD]-PEG-4-PropargylGly-Aoa-Dau (16) 
 
 
Compound 38 (1.3 eq, 2.74 mg, 3.95 mmol) was weighted in a schlenk tube and dissolved in 
tBuOH:water 1:1 (v/v) at 10 mM concentration under argon atmosphere. Compound 34 (1 eq, 2.7 
mg, 3.04 mmol) was added. CuSO4 *5H2O (0.5 eq, 0.38mg, 1.52mmol) and sodium ascorbate (0.6 
eq, 0.35 mg, 1.8 mmol) were added to the reaction, as solutions in water. The reaction was left 
under stirring for 2h. The reaction mixture was then injected directly in HPLC and purified (20-70 
ACN in 45 min). 2.7 mg (56%) of the final conjugate were obtained. MS (ESI+): m/z calculated for 
[C71H94N17O25]+= 1584.62 [M + H]+, found: 1585.99. 
 
 
Peptide Aoa-GFLG-COOH (41) 
 
 
 
 
Pentapeptide 41 was synthesized on solid phase using 2-chlorotrytil chloride resin preloaded with 
Gly (H-Gly-2CT Resin, 100-200 mesh, 0.87mmol/g, 130 mmol scale) by automated multiple solid-
phase peptide synthesis. (Boc)2Aoa-OH was manually coupled to the resin (GP9). The peptide was 
finally cleaved from the resin in the presence of Boc-Aoa (5 eq) (GP12). The solid was solubilized 
in water:tBuOH 1:3 (v/v) and lyophilized. The crude was then purified on preparative RP-HPLC 
(50-90 ACN in 45 min). the desired product was obtained as a white foam (49 mg, 80%). MS 
(ESI+): m/z calculated for [C21H32N5O7]+= 465.51 [M + H]+, found: 466.26. 
 
 
Peptide >=Aoa-GFLG-COOH (42) 
 
 
 
The aminooxyacetylated peptide 41 (30 mg, 64 µmol) was dissolved in aceton (1.8 mL) and let 
react for 30 min. Aceton was then evaporated until dryness to obtain white crystals (30 mg, 92%). 
Peptide 42 was used in the next step without purification. MS (ESI+): m/z calculated for 
[C24H36N5O7]+= 505.57 [M + H]+, found: 505.99. 
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>=Aoa-GFLG-PEG-4-c[DKPf3-RGD] (43) 
 
 
 
Peptide 42 (12.68 µmol, 6.4 mg, 2 eq) and BOP (11.41 µmol, 5.05 mg, 1.8 eq) were dissolved in 
DMF. DIPEA (34.2 µmol, 6µL, 5.4 eq) was added and the linker was pre-activated for 20 min. 
Compound 15 (6.34 µmol, 4 mg, 1 eq) was dissolved in DMF and it was added to the mixture of 
the activated linker. The reaction was left under stirring for 3h. The reaction mixture was then 
directly purified by HPLC and purified (20-70 ACN in 30 min) and the product (2 mg) was 
obtained in 28% yield. MS (ESI+): m/z calculated for [C51H72N15O14]+= 1118.22 [M + H]+, found: 
1117.94. 
 
 
Aoa-GFLG-PEG-4-c[DKPf3-RGD] (44) 
 
 
 
Peptide 43 (1.79 µmol, 2 mg, 1 eq) was dissolved in 1M CH3ONH2 HCl containing NH4OAc-
buffer (0.2 M, pH 5) (20 eq). The reaction mixture was then directly purified by semi-preparative 
HPLC and the fraction containing the product was lyofilized (1.7 mg, 88%). MS (ESI+): m/z 
calculated for [C51H72N15O14]+= 1078.16 [M + H]+, found: 1077.92.  
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-Dau-Aoa-GFLG-PEG-4-c[DKPf3-RGD] (17) 
 
 
 
The deprotected aminooxyacetylated peptide (2.7 mg, 2.5 μmol) 44 was dissolved in 0.2M 
NH4OAc (pH 5) at a peptide concentration of 10 mg/mL. Dau (1.7 mg) was added in 30% excess; 
the reaction mixture was stirred for 24h at r.t. The mixture was directly purified by HPLC (20-70 
ACN in 30 min), yielding the conjugate 17 (2.4 mg, 50%). MS (ESI+): m/z calculated for 
[C75H95N16O23]+ = 1587.67 [M + H]+, found: 1588.16.  
 
 
sC18 branched peptide for Ptx conjugate (45) 
 
 
 
Peptide 45 was synthesized on solid phase using Fmo-Rink amide resin (200 mesh, loading: 0.48 
mmol/g, 0.015 mmol scale) by automated multiple solid-phase peptide synthesis. Once the first part 
of the peptide 114FRNKIKEK121 was ready, Fmoc-L-Lys(DDe)-OH was manually coupled (GP9). 
The peptide was then subjected to elongation on the roborter for the remaining amino acids 
105LRKRLR112. The last amino acid, Fmoc-Pra-OH (propargylglycine), was manually coupled 
(GP9). After its Fmoc deprotection (GP10), Boc protection was accomplished (10 eq Boc2O, 1 eq 
DIPEA in DCM, 2h, shaking, r.t.). Resin was washed with 5xDMF, 5xDCM, 5xMeOH, 5x Et2O. 
Dde group on the Lys13 was cleaved treating the resin with 1 mL 3% (v/v) hydrazine in DMF and 
shaked for ten minutes at r.t.. The cleavage was repeated ten times. Resin was washed with 
5xDMF, 5xDCM, 5xMeOH, 5xEt2O. Fmoc-βAla-OH was manually coupled (GP9). After Fmoc 
deprotection of βAla (GP10), Fmoc-L-Cys(Trt)-OH was coupled (GP9). Fmoc deprotection of Cys 
(GP10) followed. The peptide was finally cleaved from the resin (GP12). 
The solid was solubilized in water and lyophilized. The crude was then purified on preparative RP-
HPLC (20-70 ACN in 45 min). Peptide 45 was obtained as a white foam (21.5 mg, 63%, purity 
>95%). HRMS (ESI+): m/z calculated for [C101H182N37O21S]+= 2281.4032 [M + H]+, found: 
2281.4097. 
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2’-(4-Nitrophenoxycarbonyl) paclitaxel (46) 
 
 
 
Paclitaxel (100 mg, 0.12 mmol, 1 eq) was dissolved in dry DCM (1 mL) under a nitrogen 
atmosphere. Pyridine (28 μL, 0.351 mmol, 3 eq) was added dropwise and the mixture was cooled 
to -20°C. A solution of 4-nitrophenylchloroformate (36 mg, 0.175 mmol, 1.5 eq) in dry. DCM (1 
mL) was then added under a nitrogen atmosphere. The mixture was warmed to 0°C and stirred until 
no unreacted paclitaxel was observable by TLC (approximately 4h; eluent:4:6 hexane/AcOEt). The 
mixture was then diluted with AcOEt (100 mL) and washed with a 1M aqueous solution of KHSO4 
(10 mL) and brine (10 mL). The organic phase was dried over Na2SO4 and concentrated. The crude 
residue was purified by flash column chromatography (Hexane/EtOAc 3:7) to afford 2’-(4-
nitrophenoxycarbonyl)paclitaxel (46) as a white foam (68 mg, 55%yield). 
Rf=0.26 (4:6 hexane/AcOEt); 1H NMR (400 MHz, CD2Cl2) δ = 8.25 (d, J=9.1, 2H), 8.16 (d, J=7.3, 
2H), 7.76 (d, J=7.3, 2H), 7.63 (m, 1H), 7.57 - 7.51 (m, 3H), 7.57 – 7.39 (m, 10H), 7.36 (d, J=9.1, 
2H), 6.94 (d, J=9.3, 1H), 6.31 (m, 1H), 6.27 (s, 1H), 6.08 (dd, J=9.3, 2.6, 1H), 5.67 (d, J=7.1, 1H), 
5.55 (d, J=2.8, 1H), 4.98 (d, J=8.2, 1H), 4.42 (m, 1H), 4.31 (d, J=8.4, 1H), 4.17 (d, J=8.4, 1H), 
3.81 (d, J=7.0, 1H), 2.53 (m, 1H), 2.48 (s, 3H), 2.43 (m, 1H), 2.24 (dd, J=15.5, 8.9 Hz, 1H), 2.20 
(s, 3H), 1.94 (s, 1H), 1.91 (d, J=5.3, 2H), 1.82 (m, 1H), 1.70 (s, 1H), 1.64 (s, 3H), 1.24 (s, 3H), 
1.13 (s, 3H). 13C NMR (101 MHz, CD2Cl2): d=204.1, 171.7, 170.4, 167.9, 167.5, 167.2, 155.4, 
152.2, 146.2, 142.7, 136.8, 134.1, 134.0, 133.5, 132.5, 130.6, 129.8, 129.6, 129.1, 127.5, 127.1, 
125.8, 122.1, 84.7, 81.4, 79.5, 78.4, 76.7, 75.9, 75.5, 73.0, 72.5, 58.8, 53.2, 46.1, 43.6, 36.1, 36.0, 
27.0, 23.1, 22.4, 21.0, 15.0, 9.8 ppm. 
 
 
Fmoc-Val-Ala-OH (48) 
 
 
Commercially available Fmoc-(L)-Val-OH (5.0 g, 14.9 mmol, 1 eq) was dissolved in THF and 
NHS (1.7 g, 14.9 mmol, 1 eq) was added as a solution in THF. DCC (3.0 g, 14.9 mmol, 1 eq) was 
added at 0°C. the mixture was allowed to reach room temperature and stirred for 16 hours. Then, 
the solid DCU byproduct was removed by filtration and washed with THF. The filtrate was dried 
under reduced pressure, and the resulting glassy solid was used without further purification. 
The glassy solid obtained was then solubilized in DME (dimethoxyethane, 40 ml) and added to a 
solution of H-Ala-OH (1.4 g, 15.6 mmol, 1.05 eq) and saturated NaHCO3 in water (40 ml). THF 
(22 ml) was added to aid solubility and the mixture was stirred at room temperature for 3 days. 
Acqueous citric acid (15%, 100 mL) was added, and the mixture was extracted twice with 10% iso-
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propanol/EtOAc. The organic layer was washed twice with water and then the solvents were 
evaporated to afford a white solid. The white solid was dried in vacuo and then triturated and 
sonicated with ether. The product (48) was collected by filtration, and it was obtained as white 
solid. (5.7 g, 93%). 
1H NMR (400 MHz, DMSO-d6) δ = 12.50 (bs, 1H), 8.20 (d, J=6.9, 1H), 7.89 (d, J=7.5, 2H), 7.75 (t, 
J=6.5, 2H), 7.44-7.31 (m, 5H), 4.40-4.10 (m, 4H), 3.90 (t, J=7.1, 1H), 2.06-1.85 (m, 1H), 1.27 (d, 
J=7.3, 3H), 0.97-0.75 (m, 6H). 13C-NMR (100 MHz, DMSO-d6) δ = 173.96, 170.95, 156.06, 
143.90, 143.79, 140.69, 127.63, 127.04, 125.39, 120.08, 65.67, 59.77, 47.47, 46.67, 30.50, 19.12, 
18.20, 17.10. 
 
Fmoc-Val-Ala-PAB-OH (49) 
 
 
Under nitrogen atmosphere a suspension of dipeptide 48 (913 mg, 2.2 mmol, 1 eq), 4-aminobenzyl 
alcohol (328 mg, 2.66 mmol, 1.2 eq) and EEDQ (823 mg, 3.33 mmol, 1.5 eq) in DCM was treated 
with MeOH until a clear solution was obtained. The mixture was stirred for 3 days in the dark at r.t. 
A precipitated was formed. After filtration, the precipitated was washed with diethyl ether and 
sonicated. The procedure was repeated twice and the solid was dried in high vacuo (898 mg, 78%). 
Rf = 0,13 (EtOAc/Hexane 6:4); 1H NMR (400 MHz, DMSO-d6) δ = 9.91 (s, 1H), 8.15 (d, J=7.0, 
1H), 7.89 (d, J=7.5, 2H), 7.74 (t, J=6.9, 1H), 7.53 (d, J=7.2, 2H), 7.44-7.39 (m, 3H), 7.32 (t, J=7.4, 
3H), 7.23 (d, J=8.3, 2H), 5.09 (t, J=5.6, 1H), 4.43 (d, J=5.5, 3H), 4.20-4.30 (m, 3H), 3.91 (t, J=7.9, 
1H), 2.02-1.97 (m, 1H), 1.31 (d, J=7.0, 3H), 0.90-0.85 (m, 6H). 13C-NMR (100 MHz, DMSO-d6) δ 
= 170.97, 170.86, 156.13, 143.86, 143.77, 140.69, 140.67, 137.53, 137.41, 127.62, 127.04, 126.88, 
125.34, 120.08, 118.85, 65.68, 62.56, 59.98, 48.95, 46.66, 30.36, 19.16, 18.22, 18.11. 
 
Fmoc-Val-Ala-PAB-PNP (50) 
 
 
Compound 49 (680 mg, 1.32 mmol, 1 eq) was dissolved in dry THF under nitrogen atmosphere. 
Pyridine (266 μL, 3.3 mmol, 2.5 eq) was added and the solution was cooled at 0°C. 4-
Nitrophenylchloroformate (400 mg, 1.98 mmol, 1.5 eq) was added and the stirred reaction became 
milky. The mixture was allowed to reach r.t. and stirred for 3 h. The reaction was then diluted with 
EtOAc (200 mL) and washed with 1M KHSO4 (2 x 50 mL) and brine (1 x 50 mL). The organic 
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phase was dried over Na2SO4 and concentrated. The crude residue was purified by flash 
chromatography (charged as solid load, gradient: Hexane/EtOAc 4/6) to afford the product (50) as 
a white solid (594 mg, 66%). 
Rf = 0,5 (EtOAc/Hexane 6:4); 1H NMR (400 MHz, DMSO-d6) δ = 10.07 (s, 1H), 8.31 (d, J=9.0, 
2H), 8.19 (d, J=6.8, 1H), 7.89 (d, J=7.5, 2H), 7.74 (t, J=7.2, 2H), 7.64 (d, J=8.4, 2H), 7.57 (d, 
J=9.0, 2H), 7.42-7.40 (m, 4H), 7.32 (t, J=7.3, 2H), 5.24 (s, 2H), 4.48-4.37 (m, 1H), 4.35-4.16 (m, 
3H), 3.95-3.89 (m, 1H), 2.02-1.97 (m, 1H), 1.31 (d, J=7.0, 3H), 0.90-0.85 (m, 6H). 13C-NMR (100 
MHz, DMSO-d6) δ = 171.22, 171.04, 156.13, 155.28, 151.93, 145.17, 143.86, 140.69, 139.42, 
129.46, 129.28, 127.62, 127.04, 126.17, 125.38, 122.59, 1120.07, 119.03, 70.23, 65.67, 59.94, 
49.05, 46.66, 30.37, 19.15, 18.24, 17.99. 
 
Fmoc-Val-Ala-PAB-PNP-(N-Boc)-dimethylethylendiamine (51) 
 
 
Fmoc-Val-Ala-PAB-PNP (50) (594 mg, 0.87 mmol, 1 eq) was dissolved in dry THF under nitrogen 
atmosphere. A solution of the Boc N-N-dimethylethilendiamine (328 mg, 1.74 mmol, 2 eq) and 
DIPEA (380 μL, 2.18 mmol, 2.5 eq) in dry THF was added at 0°C. the mixture was stirred 
overnight at r.t. The solvent was removed by rotary evaporation. EtOAc was then added and the 
solution was washed with 1M aqueous KHSO4 (2x) and a saturate aqueous solution of NaHCO3 
(2x). the organic phase was dried over Na2SO4 and concentrated. The crude residue was purified by 
flash chromatography (Hexane:EtOAc 3:7) to afford the product (475 mg, 74%).  
 
Rf = 0,36 (EtOAc/Hexane 7:3); 1H NMR (400 MHz, CD3OD) δ = 7.78 (d, J=7.5, 2H), 7.64 (m, 
2H), 7.57 (m, 2H), 7.38 (t, J=7.4, 2H), 7.31-7.28 (m, 4H), 5.04 (s, 2H), 4.50 (q, J=7.0, 1H), 4.40-
4.36 (m, 2H), 4.21 (t, J=6.7 1H),3.95 (d, J=6.8), 3.41-3.35 (m, 4H), 2.93 (s,rotamers A+B, 3H), 
2.84 (s, rotamr A, 3H), 2.73 (s, rotamer B, 3H), 2.12-2.04 (m, 1H), 1.43 (m, 3H) 1.41 (s, 9H), 0.98-
0.94 (m, 6H). 13C-NMR (100 MHz, CD3OD) δ = 174.10, 172.94, 158.85, 145.33, 145.17, 142.60, 
139.67, 139.54, 133.63, 130.00, 129.66, 128.78, 128.18, 126.20, 121.17, 120.93, 68.24, 67.99, 
62.26, 51.02, 48.45, 48.00, 47.65, 31.86, 28.69, 19.69, 18.66, 17.99. 
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Glutaric anhydride-Val-Ala-PAB-PNP-(N-Boc)-dimethyl ethylendiamine (52) 
 
 
The N-Fmoc protected peptide (51) (470 mg, 0.644 mmol, 1 eq) was dissolved in dry DMF (0.1M) 
under nitrogen atmosphere. Piperidine (318 μL, 3.22 mmol, 5 eq) was added and the reaction was 
stirred for 2h at r.t. the mixture was then diluted with EtOAc (20x DMF volume) and washed twice 
with saturated NaHCO3; the organic phase was dried over anhydrous Na2SO4 and concentrated 
under reduced pressure. A yellowish solid was obtained after adding DCM and evaporating. The 
crude free amine so obtained was dissolved in dry DMF (8 mL) and cooled to 0°C under N2. 
Glutaric anhydride (184 mg, 1.61 mmol, 2.5 eq), DMAP (20 mg, 0.161 mmol, 0.25 eq) and DIPEA 
(420 μL, 2.41 mmol, 3.75 eq) were added. The mixture was allowed to reach r.t. and stirred 
overnight. The reaction was then diluted with EtOAc and washed with KHSO4 and brine. The 
organic phase was dried and concentrated. The crude was then purified by flash chromatography on 
silica gel (from 100% DCM to DCM/MeOH 9:1+0.1% acetic acid), affording the final compound 
(52) in 89% yield. 
Rf = 0,32 (DCM/MeOH 95:5+0.1% acetic acid); 1H NMR (400 MHz, CD3OD) δ = 7.59 (s, 2H), 
7.33-7.31 (m, 2H), 5.05 (s, 2H), 4.51-4.45 (m, 1H), 4.18 (d, J=7.1, 1H), 3.42-3.31 (m, 4H), 2.94 (s, 
rotamers A+B, 3H), 2.85 (s, rotamer A, 3H), 2.75 (s, rotamer B, 3H), 2.37-2.31 (m, 4H), 2.14-2.05 
(m, 1H), 1.94-1.87 (m, 2H) 1.42 (s, 12H), 1.06-0.89 (m, 6H). 13C-NMR (100 MHz, CD3OD) δ = 
177.46, 175.85, 173.70, 173.03, 158.04, 157.97, 139.70, 139.56, 133.83, 133.65, 130.00, 129.68, 
121.16, 81.20, 80.90, 68.26, 67.97, 60.39, 51.08, 47.96, 47.66, 35.8, 35.58, 35.29, 35.18, 34.63, 
34.5, 31.73, 28.69, 22.35, 19.71, 18.72, 17.95. 
 
Maleimide-Glutaric anhydride-Val-Ala-PAB-PNP-(N-Boc)-dimethyl ethylendiamine 
(53) 
 
 
Compound 52 (50 mg, 0.080 mmol, 1 eq) was dissolved in dry DCM/DMF 1mL:200μL. DIC 
(18.5μL, 1.12 mmol, 1.5 eq ), NHS (13 mg, 0.112 mmol, 1.4 eq) were added and the reaction was 
stirred o.n. A solution of N-(2-aminoethyl)maleimide-TFA salt in dry DMF (500 μL) and DIPEA 
(38 μL, 0.40 mmol, 5 eq) was added to the previous solution. The reaction was stirred for 2h. After 
the removal of DMF, the reaction mixture was purified by flash column chromatography 
(DCM/MeOH from 97:3 to 9:1) affording compound 1.27 in moderate yield (33 mg, 55%). 
Rf = 0,45 (DCM/MeOH 9:1); 1H NMR (400 MHz, CD3OD) δ = 7.59 (m, 2H), 7.32 (m, 2H), 6.79 
(s, 2H), 5.49 (s, 1H), 4.48 (q, J=6.9, 1H), 4.21–4.19 (m, 1H), 3.66–3.57 (m, 3H), 3.42 – 3.33 (m, 
6H), 2.94 (s, rotamers A+B, 3H), 2.85 (s, rotamer A, 3H), 2.75 (s, rotamer B, 3H), 2.32 – 2.27 (m, 
93 
 
 
3H), 2.16–2.11 (m, 3H), 1.91–1.82 (m, 2H), 1.45–1.42 (m, 12H), 0.99 (t, J=7.4, 6H).13C NMR (100 
MHz, CD3OD) δ = 179.81, 177.48, 175.80, 175.02, 173.71, 173.01, 172.61, 139.66, 139.56, 
133.83, 133.67, 130.00, 129.68, 121.16, 81.20, 80.90, 68.20, 67.93, 60.38, 51.08, 47.96, 47.66, 
38.90, 38.45, 38.11, 35.76, 35.29, 35.18, 34.63, 34.50, 31.76, 28.69, 22.86, 19.73, 18.68, 18.02. 
MS (ESI+): m/z calculated for [C36H54N7O10]+= 744.86 [M + H]+, found: 745.09. 
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Synthesis of peptidomimetics inhibitors of Cadherins 
 
All the intermediates 71, 72 and 73 required for the synthesis of peptidomimetic 59 were 
synthesized according to literature procedure and their analytical data were in agreement with those 
already published.155 
COOH-DKP3-NHBoc (82) was synthesized as previously reported by our group and the its 
analytical data, together with those of its intermediates (77-81), were in in agreement with data 
already published.52 
 
N-indole (Mtr)-3-carboxaldehyde (64) 
 
 
 
To a solution of indole-3-carbaldehyde (1 g, 7 mmol, 1 eq) in dry THF (30 mL), DIPEA (3.6 mL, 
20.7 mmol, 3 eq) and 4-methoxy-2,3,6-trimethylbenzenesulfonyl chloride (Mtr-Cl, 1.72 g, 7 mmol, 
1 eq) were added at 0°C. The mixture was stirred for 1h at 0°C, then at room temperature for 48h. 
The crude was purified by flash chromatography on silica gel eluting EtOAc:Hexane 4:6 v/v to 
afford the product as a brown foam (540 mg, 44%). 
Rf = 0,8 (EtOAc/Hexane 7:3); 1H-NMR(400 MHz, CDCl3) δ = 10.11 (s, 1H), 8.29 (d, 1H), 8.26 (s, 
1H), 7.33 (m, 1H), 7,27 (m, 2H), 6.68 (s, 1H), 3.88 (s, 3H), 2.75 (s, 3H), 2.35 (s, 3H), 2.07 (s, 3H); 
13C-NMR (100 MHz, CDCl3) δ 185.37, 161.13, 140.63, 140.21, 136.62, 135.31, 126.43, 126.29, 
125.94, 125.87, 124.58, 122.55, 120.45, 112.66, 112.33, 55.69, 24.28, 17.36, 11.98. MS (ESI) m/z 
calcd for [C19H19NO4SNa]+: 380.09; found: 380.16 [M+Na]+. 
 
(S)-N-indolyl (Mtr) serine methyl ester (65) 
 
 
 
To a solution of indole-3-carbaldehyde-Mtr protected (63) (1.39 g, 3.89 mmol, 1 eq) in dry THF 
(54 mL),L-Ser-OMe (605 mg, 3,89 mmol, 1 eq), NaBH(OAc)3 (1.15 g, 5.45 mmol, 1.4 eq) and 
acetic acid (213 μL, 3.89 mmol, 1 eq) were added. The mixture was stirred for 18h at r.t. and then it 
95 
 
 
was diluted with EtOAc (80 mL) and washed with a saturated solution of NaHCO3. Organic phases 
were reunited, dried over Na2SO4 anhydrous, filtered and evaporated under reduced pressure. The 
crude was purified by flash chromatography on silica gel eluting EtOAc:Hexane 1:1 to afford the 
product as a yellow oil (1.15 g, 64%). 
Rf = 0,1 (EtOAc/Hexane 1:1); 1H NMR (400 MHz, CDCl3) δ = 7.67 (d, J=6.5, 1H), 7.55 (s, 1H), 
7.35 (d, J=7.1, 1H), 7.25 – 7.19 (m, 2H), 6.66 (s, 1H), 4.12 (d, J=7.5, 1H), 3.95 (d, J=13.5, 1H), 
3.88 (s, 3H), 3.86 – 3.84 (m, 1H), 3.77 (s, 3H), 3.70 – 3.66 (m 1H), 3.68 (dd, J=10.9, 6.2, 2H), 3.53 
(dd, J=6.0, 4.5, 1H), 2.96 (s, 1H), 2.74 (s, 3H), 2.36 (s, 3H), 2.08 (s, 3H); 13C-NMR (100 MHz, 
CDCl3) δ = 172.76, 160.53, 140.20, 140.08, 135.28, 129.31, 127.87, 125.81, 124.49, 122.66, 
119.66, 116.79, 112.71, 112.41, 62.28, 61.73, 60.38, 55.60, 52.35, 42.82, 24.27, 17.39, 11.95. 
MS (ESI) m/z calcd for [C23H28N2O6SNa]+: 483.16; found: 483.16 [M+Na]+. 
 
Isopeptide (66) 
 
 
(S)-N-indolyl (Mtr) serine methyl ester 65 (1.15 g, 2.50 mmol, 1 eq) was coupled with (R)-N-(tert-
butoxycarbonyl) aspartic acid β-allyl ester 20 (0.888 g, 3.25 mmol, 1.3 eq.) according to general 
procedure GP2. The residue was purified by flash chromatography on silica gel eluting 
(Hex/EtOAc 6:4) to afford the desired products as a white foam in 80% yield. 
 
Rf = 0,7 (EtOAc/Hexane 6:4); 1H NMR (400 MHz, CDCl3) δ = 7.69 (d, J=7.0, 1H),7.52 (s, 1H), 
7.33 (d, J=7.4, 1H), 7.22-7.15 (m, 2H), 6.64 (s, 1H), 5.87 (ddt, J=16.3, 10.9, 5.6, 1H), 5.50 (d, 
J=7.8, 1H), 5.25 (dd, J=28.8, 13.8, 2H), 4.58 (d, J=5.5, 1H), 4.54 (t, J=6.1, 2H), 4.47 (dd, J=11.0, 
4.4, 1H), 4.35 (dd, J=10.9, 4.5, 1H), 4.05 (d, J=13.4, 1H), 3.89 (d, J=13.8, 1H),3.85 (s,3H), 3.74 
(s,3H), 3.60 (t, J=4.1, 1H), 2.97 (d, J=16.7, 1H), 2.84 (dd, J=16.9, 4.5, 1H), 2.72 (s, 3H), 2.34 (s, 
3H), 2.06 (s, 3H), 1.43 (s, 9H). 13C-NMR (100 MHz, CDCl3) δ = 172.24, 170.60, 170.46, 160.45, 
155.25, 140.12, 140.00, 135.29, 131.69, 129.45, 127,96, 125.71, 124.51, 124.33, 122.47, 120.01, 
118.54, 117.59, 112.55, 112.39, 80.10, 65.85, 65.63, 58.97, 55.57, 52.24, 49.94, 42.88, 36.71, 
28.26, 24.24, 17.37, 11.93. MS (ESI) m/z calcd for [C35H45N3O11SNa]+: 738.82; found: 738.23 
[M+Na]+. 
 
 
 
 
 
 
96 
 
 
 
OH-DKP3-Indolyl-COOAllyl (67) 
 
 
 
Compound 66 (486 mg, 0.694 mmol, 1 eq) was deprotected according to the general procedure 
GP1. The TFA salt was then solved in isopropanol (10 mL) and DIPEA (480 μL, 2.78 mmol, 4 eq) 
was added at r.t., monitoring the formation of the DKP by TLC (EtOAc). The crude was then 
concentrated under reduced pressure and purified by flash chromatography on silica gel eluting 
hexane:EtOAc (from 1:9 to 100% EtOAc). The product was recovered as a white foam (80%). 
Rf = 0,3 (EtOAc); 1H NMR (400 MHz, CDCl3) δ = 7.74 (s, 1H), 7.65 – 7.63 (m, 1H), 7.49 (s, 1H), 
7.35 – 7.31 (m, 1H), 7.26 – 7.23 (m, 2H), 6.71 (s, 1H), 5.97 – 5.87 (ddd, J = 16.2, 11.0, 5.8 Hz, 
1H), 5.55 (d, J = 15.2 Hz, 1H), 5.38 – 5.25 (m, 2H), 4.76 – 4.73 (dd, J = 7.7, 3.8 Hz, 1H), 4.68 – 
4.58 (m, 2H), 4.33 (d, J = 15.2 Hz, 1H), 4.13 – 4.01 (m, 2H), 3.94 (s, 1H), 3.93 (s, 3H), 3.31 (dd, J 
= 17.4, 3.8 Hz, 1H), 2.90 (dd, J = 17.4, 8.0 Hz, 1H), 2.77 (s, 3H), 2.40 (s, 3H), 2.13 (s, 3H).  13C-
NMR (100 MHz, CDCl3) δ = 170.73, 168.29, 166.56, 160.56, 140.04, 140.05, 135.08, 131.59, 
128.81, 127.64,126.23, 125.88, 124.73, 122.93, 119.83, 118.72, 113.60, 112.52, 112.45, 65.80, 
61.37, 61.13, 55.60, 51.21, 38.30, 37.12, 24.20, 17.36, 11.96. MS (ESI) m/z calcd for 
[C29H33N3O8SNa]+: 606.20; found: 606.68 [M+Na]+. 
 
N3-DKP3-Indolyl-COOAllyl (68) 
 
 
 
Compound 67 (790 mg, 1.35 mmol, 1 eq) was solved in dry DCM: dry Toluene 1:2, under nitrogen 
atmosphere. The solution was cooled at -20°C and PPh3 (460 mg, 1.75 mmol, 1.3 eq) was added. 
HN3 (1.35 M in toluene, 8.7 mmol, 6.5 mL, 6.5 eq,) and DIAD (372 μL, 1.89 mmol, 1.4 eq) were 
sequentially added dropwise under these conditions. The reaction was stirred at -20°C for 5h. the 
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mixture was purified and charged directly on silica gel column chromatography eluting 
hexane/EtOAc 3:7. The desired product was obtained as white foam (88%). 
Rf = 0,46 (EtOAc/Hexane 8:2); 1H NMR (400 MHz, CDCl3) δ = 7.63 (s, 1H), 7.54-7.51 (m, 1H), 
7.28-7.26 (m, 1H), 7.21-7.19 (m, 2H), 6.68 (s, 1H), 6,64 (s, 1H), 5.93-5.84 (m, 1H), 5.44 (d, J = 
15.2, 1H), 5.35-5.25 (m, 2H), 4.62-4.53 (m, 3H), 4.26 (d, J = 15.2, 1H), 3.97 (t, 1H), 3.91 (dd, J = 
12.7-3.2, 1H), 3.86 (s, 3H), 3.77 (dd, J = 12.7-3.2, 1H), 3.35 (dd, J = 17.5-3.1, 1H), 2.76 (dd, J = 
20.2-10.6, 1H), 2.70 (s, 3H), 2.32 (s, 3H), 2.06 (s, 3H). 13C-NMR (100 MHz, CDCl3) δ = 171.12, 
166.34, 166.09, 161.12, 140.60, 140.52, 135.63, 131.87, 128.98, 128.01, 126.65, 126.43, 125.45, 
123.56, 120.08, 119.63, 113.67, 113.18, 112.95, 66.45, 58.69, 56.08, 52.15, 51.59, 39.05, 37.88, 
24.71, 17.83, 12.44. MS (ESI) m/z calcd for [C29H33N6O7SNa]+: 609.67; found: 609.82 [M+H]+ 
 
 
NHBoc-DKP3-Indolyl-COOAllyl (69) 
 
 
 
Compound 68 (365 mg, 0.6 mmol, 1 eq) was dissolved in dry THF (11 mL) under nitrogen 
atmosphere and the solution was cooled at -20°C. Me3P (1.2 mL, 1.2 mmol, 2 eq) and Boc-ON 
(295 mg, 1.2 mmol, 2 eq) were sequentially added under these conditions. The mixture was 
allowed to reach room temperature and it was stirred for 5h. After dilution with DCM the reaction 
mixture was sequentially washed with distilled water (3 x 30 mL) and brine (2 x 30 mL). The 
organic phase was then dried over Na2SO4 anhydrous and volatiles were removed under reduced 
pressure; then under vacuum. The crude was purified by flash chromatography on silica gel eluting 
hexane:EtOAc (from 4:6). The product was recovered as a yellowish foam (70%). 
Rf = 0,6 (EtOAc/Hexane 8:2); 1H NMR (400 MHz, CDCl3) δ = 7.67 (s, 1H), 7.55-7.53 (m, 1H), 
7.28-7.27 (m, 1H), 7.20-7.17 (m, 2H), 6.73 (s, 1H), 6,62 (s, 1H), 5.92-5.82 (m, 1H), 5.64 (d, J = 
15.2, 1H), 5.33-5.24 (m, 2H), 5.01 (s, 1H), 4.62 (m, 2H), 4.46 (d, J = 7.9, 1H), 4.29 (d,J = 15.1, 
1H), 3.88 (s, 1H), 3.85 (s, 3H), 3.81-3.78 (m, 1H), 3.56 (d, J =11.7, 1H), 3.37 (dd, J =17.5-2.1, 1H), 
2.69 (m, 4H), 2.32 (s, 3H), 2.05 (s, 3H), 1.46 (s, 9H). 13C-NMR (100 MHz, CDCl3) δ = 171.02, 
166.93, 164.70, 160.70, 147.91, 140.23, 140.21, 135.30, 131.52, 128.97, 127.83, 126.82, 126.04, 
124.90, 123.09, 119.93, 119.29, 113.58, 112.78, 112.58, 66.15, 58.75, 55.74, 51.18, 40.97, 38.21, 
38.19, 28.48, 24.39, 17.51, 12.12. MS (ESI) m/z calcd for [C34H43N8O9S]+: 683.79; found: 684.11 
[M+H]+. 
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NHBoc-DKP3-Indolyl-COOH (70) 
 
 
 
Compound 69 (438 mg, 0.641 mmol, 1 eq) was dissolved in dry DCM (13 mL) and it was cooled 
to 0°C. Pyrrolidine (101 μL, 1.22 mmol, 1.9 eq), Ph3P (67 mg, 0.256 mmol, 0.4 eq) and [Pd(Ph3P)4] 
(52 mg, 0.045 mmol, 0.07 eq) were sequentially added at 0°C. The reaction mixture was stirred 
under these conditions. After 1h, the mixture was diluted with EtOAc and acidified with a 1M 
KHSO4; the phases were separated and the aqueous phase was extracted twice with EtOAc. 
Organic layers were reunited, dried over Na2SO4 anhydrous and volatiles were removed under 
reduced pressure, then under vacuum. The crude was taken up with DCM and filtered over a small 
pad of celite. The product (402 mg, quantitative) was used without further purification. 
 
 
NHBoc-DKP3-Indolyl-Ile-NHtBu (75) 
 
 
 
Compound 73 (65 mg, 0.229 mmol, 1 eq) was deprotected according the general procedure GP1. 
The corresponding TFA salt (74) was then coupled with 70 (147 mg, 0.229 mmol, 1 eq) according 
to general procedure GP2. The residue was purified by flash chromatography on silica gel 
(DCM/MeOH 97:3) to afford the desired product (75) as a yellowish foam (115 mg, 62%). 
Rf = 0,2 (DCM/MeOH 95:5); 1H-NMR (400 MHz, CDCl3) δ = 7.69 (s, 1H), 7.59 – 7.42 (m, 2H), 
7.24 (s, 1H), 7.19 – 7.08 (m, 2H), 7.06 (br s, 1H), 6.62 (s, 1H), 6.28 (br s, 1H), 5.71 (br s, 1H), 5.60 
(d, J=15.2, 1H), 4.49 (d, J=6.4, 1H), 4.29 (d, J=15.2, 1H), 4.17 (t, J=8.1, 1H), 3.81 (m, 5H), 3.49 
(m, 1H), 3.23 (d, J=14.4, 1H), 2.68 (s, 4H), 2.37 (s, 1H), 2.31 (s, 3H), 2.03 (s, 3H), 1.73 (s, 1H), 
1.42 (s, 10H), 1.28 (s, 9H), 1.10 (m, 1H), 0.96 – 0.70 (m, 6H).13C-NMR (100 MHz, CDCl3) δ = 
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170.63, 170.18, 167.30, 165.73, 160.66, 156.39, 140.22, 140.14, 135.23, 129.04, 127.86, 126.79, 
125.99, 124.79, 123.12, 119.90, 113.65, 112.66, 112.56, 58.82, 58.41, 55.71, 51.66, 40.80, 38.75, 
38.28, 37.69, 28.73, 28.50, 25.30, 24.34, 17.51, 15.37, 12.10, 11.24. MS (ESI) m/z calcd for 
[C41H59N6O9S]+: 812.01; found: 812.93 [M+Na]+. 
 
 
Boc-Asp(OtBu)-DKP3-Indolyl-Ile-NHtBu (76) 
 
 
 
Compound 75 (35 mg, 0.043 mmol, 1 eq) was deprotected according the general procedure GP1. 
The corresponding TFA salt was then coupled with Boc-L-Asp(OtBu)-OH (109 mg, 0.337 mmol, 3 
eq) according to general procedure GP2. The residue was purified by flash chromatography on 
silica gel (DCM:MeOH 95:5) to afford the desired product (76) as white foam (29 mg, 67%). 
Rf = 0,5 (DCM/MeOH 9:1); 1H NMR (400 MHz, CDCl3) δ = 7.71 (s, 1H), 7.53-7.51 (m, 1H), 7.28-
7.26 (m, 1H, overlapping with solvent signal), 7.21-7.17 (m, 2H), 7.05 (br s, 1H), 6.63 (s, 1H), 6.52 
(br. s, 1H), 5.77 (br s, 1H), 5.63-5.59 (m, 2H), 4.56 (d, J = 5.6, 1H), 4.42 (s, 1H), 4.31 (d, J = 15.2, 
1H), 4.14 (s, 1H), 4.03-4.01 (m, 1H), 3.89 (s, 1H), 3.85 (s, 3H), 3.60 (d, J = 12.0, 1H), 3.18 (d, J = 
15.8, 1H), 2.88-2.90 (m, 1H), 2.69 (s, 3H), 2.62-2.56 (m, 2H), 2.32 (s, 3H),2.06 (s, 3H), 1.51-.48 
(m, 1H), 1.44 (s, 9H), 1.42 (s, 9H), 1.28 (s, 9H), 1.16-1.11 (m, 2H), 0.92-0.88 (m, 6H). 13C-NMR 
(100 MHz, CDCl3) δ = 172.16, 170.76, 170.18, 168.25, 165.52, 160.69, 150.79, 147.28, 140.18, 
136.36, 129.03, 127.18, 126.04, 124.84, 123.15, 119.85, 113.60, 112.76, 112.59, 58.33, 58.21, 
55.75, 38.00, 28.80, 28.44, 28.22, 25.37, 24.40, 23.07, 17.55, 15.43, 12.15, 11.49, 10.44. MS (ESI) 
m/z calcd for [C49H71N7O12SNa]+: 1004.49; found: 1004.72 [M+Na]+. 
 
NHBoc-DKP3-Gly(OBn) (84) 
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NHBoc-DKP3-COOH (82) (460 mg, 1.17 mmol, 1 eq) was coupled with Gly-OBn HCl (177 mg, 
1.41 mmol, 1.2 eq) according to general procedure GP2. The residue was purified by flash 
chromatography on silica gel (DCM/MeOH from 93:7 to 90:10) to afford the desired product as a 
white foam (580 mg, 93%). 
Rf = 0,58 (DCM/MeOH 9:1); 1H NMR (400 MHz, acetone-d6) δ = 7.81 (t, J=5.4, 1H), 7.43-7.26 
(m, 10H), 6.53 (bs 1H), 5.42 (d, J=15.3), 5.18 (s, 2H), 4.52 (m, 1H), 4.11-4.01 (m, 3H), 3.84-3.81 
(m, 2H), 3.53-3.50 (m, 1H), 3.18 (dd, J=15.7, 3.5, 1H), 2.69 (dd, J=15.7, 8.8, 1H), 1.42 (s, 9H). 
13C-NMR (100 MHz, acetone-d6) δ = 171.58, 170.46, 167.58, 167.02, 156.90, 137.79, 137.02, 
129.48, 129.31, 129.06, 128.95, 128.88, 128.29, 67.13, 60.80, 52.09, 47.78, 41.81, 41.38, 38.50, 
28.63. MS (ESI) m/z calcd for [C28H34N4O7Na]+: 561.6; found: 560.98 [M+Na]+. 
 
Fmoc-Trp(Boc)-DKP3-Gly(OBn) (85) 
 
 
 
Compound 84 (80 mg, 0.148 mmol, 1 eq) was deprotected according the general procedure GP1. 
The corresponding TFA salt was then coupled with Fmoc-Trp(Boc)-OH (93 mg, 0.177 mmol, 1.2 
eq) according to general procedure GP2. The residue was purified by flash chromatography on 
silica gel (DCM:MeOH from 97:3 to 9:1) to afford the desired product as white foam (83 mg, 
60%). 
Rf = 0,6 (DCM/MeOH 9:1); 1H NMR (400 MHz, acetone-d6) δ = 8.20 (m, 1H), 8.12 (d, J=7.7, 1H), 
7.86 (s, 1H), 7.68-7.70 (m, 5H), 7.55 (t, J=8.31, 2H), 7.39-7.18 (m, 17H), 5.47 (d, J=15.3, 1H), 
5.05 (s, 2H), 4.76-4.70 (m, 2H), 4.30-4.24 (m, 1H), 4.20 (d, J=15.3, 1H), 4.13-4.08 (m, 2H), 3.99-
3.98 (m, 4H), 3.81-3.79 (m, 1H), 3.42-3.26 (m, 1H), 3.20-3.14 (m, 2H), 2.82 (dd, J=16.0, 7.4, 1H), 
2.72 (s, 3H), 1.57 (s, 9H). 13C-NMR (100 MHz, acetone-d6) δ = 173.61, 171.36, 170.43, 167.73, 
167.19, 157.14, 150.18, 144.83, 141.86, 137.41, 136.78, 136.22, 134.80, 134.69, 131.39, 131.19, 
131.07, 129.39, 129.18, 128.88,  128.83, 128.34, 128.20, 127.83, 126.20, 126.08, 125.09, 124.97, 
123.24, 120.61, 120.07, 115.80, 67.42, 67.06, 60.18, 55.87, 52.00, 47.73, 47.61, 41.74, 40.10, 
38.27, 28.34, 28.19. MS (ESI) m/z calcd for [C54H54N6O10Na]+: 970.06; found: 969.66 [M+Na]+. 
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Cbz-Arg(Mtr)-Trp(Boc)-DKP3-Gly(OBn) (86) 
 
 
The N-Fmoc protected peptide 85 (83 mg, 0.0876 mmol, 1 eq) was diluted in dry DMF (876 μL) 
under nitrogen atmosphere and treated with piperidine (43 μL, 0.438, 5 eq). The mixture was 
stirred for 2 h. After dilution with EtOAc, the mixture was washed twice with saturated NaHCO3; 
the organic phase was dried over Na2SO4 and concentrated. The product was obtained as a 
yellowish solid and it was used in the next step without purifications. The N-Fmoc deprotected 
peptide (83 mg, 0.0876 mmol, 1 eq) was then coupled with Cbz-Arg(Mtr)-OH (65 mg, 0.105 
mmol, 1.2 eq) according to general procedure GP2. The residue was purified by flash 
chromatography on silica gel (DCM:MeOH from 95:5 to 9:1) to afford the desired product as white 
foam (78 mg, 72%). 
 
Rf = 0,5 (DCM/MeOH 9:1); 1H NMR (400 MHz, acetone-d6) δ = 8.09 (d, J=8.0, 1H), 7.89 (m, 2H), 
7.80 (t, J=5.6, 1H), 7.67 (s, 1H), 7.61 (d, J=7.7, 1H), 7.56 (s, 1H), 7.45 – 7.09 (m, 17H), 6.66 (s, 
1H), 6.53 (br s, 3H), 5.61 (s, 1H), 5.38 (d, J=15.3, 1H), 5.10 (s, 2H), 5.02 (dd, J=34.2, 12.5, 2H), 
4.81 (m, 1H), 4.64 (m, 1H), 4.28 (m, 1H), 4.11 (d, J=15.4, 1H), 4.02 (m, 2H), 3.97 – 3.85 (m, 3H), 
3.80 (m, 5H), 3.24 (m, 3H), 3.12 (m, 3H), 2.74 (dd, J=15.9, 7.8, 1H), 2.68 (s, 3H), 2.63 (s, 3H), 
2.08 (s, 3H), 1.89 – 1.74 (m, 1H), 1.72 – 1.57 (m, 11H), 1.56 – 1.47 (m, 2H). 13C-NMR (100 MHz, 
acetone-d6) δ =. 173.27, 171.67, 170.52, 167.57, 167.31, 158.96, 157.61, 157.11, 150.30, 139.16, 
137.96, 137.37, 137.13, 136.92, 136.25, 135.68, 131.33, 129.50, 129.29, 129.19, 128.93, 128.69, 
128.63, 128.35, 125.21, 125.08, 124.88, 123.29, 120.03, 117.03, 115.84, 112.51, 67.19, 66.98, 
60.21, 55.87, 55.83, 55.31, 54.32, 51.96, 47.70, 43.77, 41.83, 40.18, 38.13, 28.30, 27.88, 26.08, 
24.32, 18.73, 13.22. MS (ESI) m/z calcd for [C63H74N10O14SNa]+: 1250.40; found: 1248.99 
[M+Na]+. 
  
102 
 
 
NH2-Arg(Mtr)-Trp(Boc)-DKP3-Gly-COOH (87) 
 
 
A solution of compound 86 (78 mg, 0.0635 mmol, 1 eq) in THF/H2O 1:1 v/v (23 mL) was treated 
with 10% Pd/C (15 mg, 0.0138 mmol, 0.2 eq), and the flask was purged three times with 
vacuum/H2. The mixture was stirred at r.t. overnight under H2 atmosphere, then filtered through a 
pad of celite and the celite cake was washed thoroughly with THF/H2O1:1 (v/v). the solvents were 
removed under vacuum to give the crude product 87 as a yellowish solid (75 mg, quantitative), 
which was used without further purification. 
 
C[Arg(Mtr)-Trp(Boc)-DKP3-Gly] (88) 
 
 
 
Compound 87 (75 mg, 0.0739 mmol, 1 eq) was cyclized in the presence of HATU (126 
mg, 0.332, 4.5 eq), HOAt (45 mg, 0.332, 4.4 eq) and DIPEA (77 μL, 0.443 mmol, 6 eq) 
under the conditions described in GP4. The crude was purified by flash chromatography 
on silica gel (DCM:MeOH from 95:5) to afford the desired product as white foam (40 mg, 60%).  
Rf = 0,3 (DCM/MeOH 9:1); 1H NMR (400 MHz, acetone-d6) δ = 8.10 (d, J=8.2, 1H), 8.01 (s, 1H), 
7.88 (d, J=6.4, 1H), 7.80 (br s, 1H), 7.54 (s, 1H), 7.51 (d, J=7.8, 1H), 7.41 – 7.26 (m, 6H), 7.25 – 
7.12 (m, 2H), 6.68 (s, 1H), 6.43 (br s, 1H), 6.33 (br s, 1H), 5.49 (d, J=14.8, 1H), 5.21 (d, J=11.2, 
1H), 4.88 - 4.86 (m, 1H), 4.59 – 4.45 (m, 1H), 4.44 – 4.36 (m, 1H), 4.27 (d, J=14.9, 1H), 4.19 (dd, 
J=13.3, 6.9, 1H), 3.97 (s, 1H), 3.83 (s, 3H), 3.66 – 3.49 (m, 2H), 3.33 – 3.31 (m, 1H), 3.21 – 3.02 
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(m, 4H), 2.70 (s, 3H), 2.65 (s, 3H), 2.11 (s, 3H), 2.03 – 1.92 (m, 2H), 1.92 – 1.75 (m, 1H), 1.64 (s, 
9H), 1.56 (d, J=6.6, 2H), 1.44 (d, J=6.5, 2H). 13C-NMR (100 MHz, acetone-d6) δ =. 174.39, 174.04, 
173.50, 172.84, 168.31, 167.32, 158.88, 157.56, 150.26, 139.13, 137.04, 136.92, 136.33, 136.15, 
130.99, 129.83, 129.03, 128.86, 125.48, 125.32, 124.79, 123.14, 119.98, 116.80, 116.05, 112.50, 
67.69, 61.36, 56.01, 55.87, 55.76, 54.01, 51.45, 49.21, 47.62, 45.43, 41.33, 39.63, 35.79, 28.29, 
27.63, 27.28, 25.38, 24.28, 19.44, 18.68, 17.59, 17.15, 12.12. MS (ESI) m/z calcd for 
[C48H60N10O11SNa]+: 1008.13; found: 1008.33 [M+Na]+. 
 
C[Arg-Trp-DKP3-Gly] (61) 
 
  
Compound 88 (5 mg, 0.0052 mmol) was treated with TFA (150 μL), in the presence of ion 
scavengers thioanisole (8 μL), ethanedithiol (5 μL) and anisole (3 μL). The mixture was 
stirret at r.t. for 2h. All volatiles were then evaporated and the crude was dissolved in a 
mixture of water and diisopropyl ether 1:1 (5 mL). The aqueous phase was washed several 
times with diisopropyl ether and then concentrated under reduced pressure to give the 
crude compound. It was purified by semipreparative-HPLC [gradient: 90% H2O + 0.1% 
TFA/ 10% CH3CN + 0.1% TFA to 30% H2O + 0.1% TFA/ 70% CH3CN + 0.1% TFA] in 
12 min; flow: 5 mL/min, tR (product) = 4 min c.a. to afford the desired product 61 as white 
foam (1 mg, 30%). MS (ESI) m/z calcd for [C33H41N10O6]+:673.75; found:673.22 [M+H]+. 
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Synthesis of cyclic CPP-DKP scaffold for drug delivery 
 
DKP1 and DKP3 scaffolds, 97 and 80 respectively, were synthesized according to previously 
reported procedures and their analytical data were in agreement with those already published.52  
 
N3-DKP1-COOH (98) and N3-DKP3-COOH (99) 
 
 
Allyl-protected peptide (97 or 80) (230 mg, 0.644 mmol, 1 eq) was dissolved in dry DCM (6 mL) 
under a nitrogen atmosphere, and the mixture was cooled to 0°C. [Pd(PPh3)4] (223 mg, 0.193, 0.3 
eq) and freshly distilled N-methylaniline (84 μL, 0.773 mmol, 1.2 eq) were added successively. 
The mixture was then allowed to reach r.t. After 1h of stirring, the mixture was diluted with EtOAc 
(40 mL) and extracted with acqueous NaHCO3 (4 x 20 mL). The combined acqueous phase were 
acidified to pH 2 by adding KHSO4 (1 M solution) and then extracted with DCM (4 x 20 mL). The 
resulting organic phase was dried over Na2SO4 and the solvent was evaporated to afford the desired 
as a slightly yellow solid (121 mg, 60%) which was used without further purification. Rf= 0.2 
(DCM/MeOH 9:1); 
 
sC18*-DKP-NH2 103a and 103b 
 
sC18* (106GLRKRLRKFRNK117) was synthesized on a 2-chlorotrytil chloride resin (H-L-
Lys(Boc)-2CT, loading: 0.74mmol/g, 0.015 mmol scale) by automated multiple solid-phase peptide 
synthesis (Fmoc strategy) using a robot system. 98 or 99 were coupled to the peptide according to 
GP13. The azido group was reduced following GP14. Then cleavage from the resin was done 
according to GP15. 
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Cyclic(sC18*-DKP1) (92) and c(sC18*-DKP3) (93) 
 
10 mg (5.42mmol, 1 eq) of the full protected linear peptide 103a, b were dissolved in 8,3 ml 
(0.65mM) of dry DMF, under nitrogen atmosphere. PyBOP (14.1mg, 27.1µmol, 5eq), HOBt 
(3.7mg, 27.1µmol, 5eq) and DIPEA (5.66 µL, 35.5µmol, 6eq) were added under these conditions. 
The reaction was left under stirring at 4°C for 48h. The mixture was then diluted with EtOAc and 
extracted with brine and saturated NaHCO3. The organic phase was then dryied at reduced pressure 
and directly subjected to full cleavage according to GP16. The crude was then purified on 
semipreparative RP-HPLC (10-60 ACN in 45 min, tR = 24 min). The peptide was freeze-dried 
from water obtaining a white solid (1.6 mg, 16%). LC/MS: m/z calculated for [C83H140N31O16]+= 
1828.23, found fragmentation patterns: [M+2]2+ = 914.6, [M+3]3+ = 610.8, [M+4]4+ = 457.9, 
[M+5]5+ = 366.6. 
 
 
Linear sC18*-DKP1 (108) 
 
 
The sequence 106GLRKRLRK113 was synthesized on a 2-chlorotrytil chloride resin (H-L-Lys(Boc)-
2CT, loading: 0.74mmol/g, 0.015 mmol scale) by automated multiple solid-phase peptide synthesis 
(Fmoc strategy) using a robot system. 98 was coupled to the peptide according to GP13. The azido 
group was reduced following GP14. Fmoc-L-Lys(Boc)-OH was manually coupled following GP9. 
Fmoc deprotection was then accomplished (GP10). The resin was subjected to automated 
elongation for the remaining amino acids. Then the peptide was cleaved from the resin (GP15). 
The solvent was evaporated under reduced pression. 28 mg of linear peptide 108 were obtained. 
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Linear sC18*(reversed sequence)-DKP1 (113) 
 
 
sC18 reversed sequence (117KNRFKRLRKRLG106) was synthesized on a 2-chlorotrytil chloride 
resin (H-Gly-2CT, loading: 0.87 mmol/g, 0.015 mmol scale) by automated multiple SPPS (Fmoc 
strategy) using a robot system. DKP-1 (98) was coupled (GP13). The resin was treated according 
to GP14. Then cleavage from the resin (GP15). 27 mg of linear peptide were obtained. 
 
 
c-sC18*(reversed sequence)-DKP1 (109) 
 
 
 
7 mg (5.42mmol, 1 eq) of the full protected linear peptide 113 were dissolved in 5,8 ml (0.65mM) 
of dry DCM:dry DMF 9:1 v/v, under nitrogen atmosphere. PyBOP (9.8 mg, 18.9 µmol, 5eq), HOBt 
(2.5 mg, 18.9 µmol, 5eq) and DIPEA (3.9 µL, 22.7 µmol, 6 eq) were added under these conditions. 
The reaction was left under stirring at r.t. for 6 days. The mixture was then diluted with EtOAc and 
extracted with brine and saturated NaHCO3. The organic phase was then dryied under vacuum and 
the subjected to full deprotection. The peptide was fully deprotected according to GP16. The crude 
was purified on semipreparative RP-HPLC (10-60 ACN in 45 min, tR = 22 min). The peptide was 
freeze-dried from water obtaining a white solid (0.3 mg, 3%). LC/MS: m/z calculated for 
[C83H140N31O16]+= 1828.23, found fragmentation patterns: [M+2]2+ = 914.6, [M+3]3+ = 610.8, 
[M+4]4+ = 457.9, [M+5]5+ = 366.6. 
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Linear sC18*-DKP1 (114a) and linear sC18*-DKP3 (114b) 
 
 
The sC18* (106GLRKRLRKFRNK117) was synthesized on a 2-chlorotrytil chloride resin (H-L-
Lys(Boc)-2CT, loading: 0.74mmol/g, 0.015 mmol scale) by automated multiple solid-phase peptide 
synthesis (Fmoc strategy) using a robot system. 98 or 99 were coupled to the peptide according to 
GP13. The azido group was reduced following GP14. Then cleavage from the resin was done 
according to GP16.  
The peptides were freeze-dried from water obtaining a white solid (60% yield for 114a and 48% 
yield for 114b). LC/MS: m/z calculated for [C83H142N31O16]+= 1846.24, found fragmentation 
patterns: [M+2]2+ = 923.6, [M+3]3+ = 616.1, [M+4]4+ = 462.3, [M+5]5+ = 370.0. 
  
108 
 
 
HPLC traces of the Final Products  
 
HPLC trace of c[DKPf3-RGD]-PropargylGly-Aoa=Dau (16), purity: 96% 
 
HPLC trace of c[DKPf3-RGD]-GLFG-Aoa=Dau (17), purity: 98% 
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HPLC traces of linear sC18*-DKP 114a. Purity: > 98% 
 
HPLC traces of linear sC18*-DKP 114b. Purity: > 98% 
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Appendix of NMR spectra 
 
  
111 
 
 
2’-(4-Nitrophenoxycarbonyl) paclitaxel (46) 
1H-NMR (400 MHz, CD2Cl2) 
 
13C-NMR (101 MHz, CD2Cl2) 
 
 
112 
 
 
Glutaric anhydride-Val-Ala-PAB-PNP-dimethyl ethylendiamine (52) 
1H-NMR (400 MHz, CD3OD) 
 
13C-NMR (101 MHz, CD3OD) 
 
 
113 
 
 
Maleimide-Glutaric anhydride-Val-Ala-PAB-PNP-dimethyl ethylendiamine (53) 
1H-NMR (400 MHz, CD3OD) 
 
13C-NMR (101 MHz, CD3OD) 
 
 
114 
 
 
N-indole (Mtr)-3-carboxaldehyde (64) 
1H-NMR (400 MHz, CDCl3) 
 
 
13C-NMR (101 MHz, CDCl3)
 
115 
 
 
(S)-N-indolyl (Mtr) serine methyl ester (65) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
 
116 
 
 
Isopeptide (66) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3)
 
 
117 
 
 
OH-DKP3-indolyl-COOAllyl (67) 
1H-NMR (400 MHz, CDCl3) 
 
 
13C-NMR (101 MHz, CDCl3)
 
118 
 
 
N3-DKP3-indolyl-COOAllyl (68) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
 
119 
 
 
NHBoc-DKP3-indolyl-COOAllyl (69) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
 
120 
 
 
NHBoc-DKP3-indolyl-Ile-NHtBu (75) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
 
121 
 
 
OtBu-Asp(NHBoc)-DKP3-indolyl-Ile-NHtBu (76) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
 
122 
 
 
NHBoc-DKP3-Gly(OBn) (84) 
1H-NMR (40 MHz, Acetone-d6) 
 
13C-NMR (101 MHz, Acetone-d6) 
 
 
123 
 
 
Fmoc-Trp(Boc)-DKP3-Gly(OBn) (85) 
1H-NMR (40 MHz, Acetone-d6) 
 
13C-NMR (101 MHz, Acetone-d6) 
 
 
124 
 
 
Cbz-Arg(Mtr)-Trp(Boc)-DKP3-Gly(OBn) (86) 
1H-NMR (40 MHz, Acetone-d6) 
 
13C-NMR (101 MHz, Acetone-d6) 
 
 
125 
 
 
C[Arg(Mtr)-Trp(Boc)-DKP3-Gly] (88) 
1H-NMR (40 MHz, Acetone-d6) 
 
13C-NMR (101 MHz, Acetone-d6) 
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